[{"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nThe reason was that the results were overwhelmingly compelling \u2014 men taking the drug were not getting prostate cancer.\nThe concern was that the drug might be preventing cancers that never spread.\nThe study researchers, though, wondered if that conclusion was correct.\nMaybe, they thought, by shrinking the prostate, the drug was just making it easier to find aggressive tumors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included an estimated price for the generic version of this medication.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion\u00a0about the actual or anticipated added costs of the new nuclear imaging tests compared to current diagnostic tests. Nor is there a sense of the overall costs of treatment.", "answer": 0}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nThe device is intended for patients 75 and older with severe to profound vision impairment that has been stable over time due to blind spots from end-stage AMD.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost as there was in the competing AP story. ", "answer": 0}, {"article": "The drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThe increased risks, while double in relative terms, are small.\nThe Food and Drug Administration undertook a combined analysis of 199 clinical trials with 43,892 patients and found 4 suicides and 105 reports of suicidal symptoms among the 27,863 patients who were given the drugs compared to no suicides and 35 reports of suicidal symptoms among the 16,029 patients treated with placebos.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the average cost of these drugs.\u00a0 This is important information, especially for epileptic and bipolar patients who often take medications for most of their life.\u00a0\u00a0 \nThe drugs under discussion are fairly expensive drugs (approximately. $150-200/month for the newer drugs). There are older, and less expensive medications that might work as well for some people.\u00a0 \n ", "answer": 1}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nThe medicine, if approved, could hold promise for patients with moderate to severe persistent asthma that is not well controlled by standard drugs.\nWenzel, director of the Asthma Institute at the University of Pittsburgh, said other drugmakers have tested medicines that block one or both of the proteins, but without success.\nBut she cautioned that longer trials are needed to fully assess the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no cost information in the story.\nThe cost of existing monoclonal antibodies used to treat rheumatoid arthritis and other diseases can be in the thousand of dollars per month with many insurance companies either restricting access or requiring large patient co-pays.", "answer": 0}, {"article": "At week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\nAn ongoing phase III trial is continuing to test the safety and efficacy of guselkumab as a psoriasis treatment.\nThe disease affects nearly 3 percent of the world's population, according to the World Psoriasis Day consortium, but about half of all patients with psoriasis do not get any treatment, Dr. Gordon said.\nThis study was supported by Janssen Research and Development, the manufacturer of guselkumab.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. While guselkumab is not yet on the market, HealthNewsReview.org\u00a0has long argued that if it is worth discussing a drug\u2019s treatment potential, it\u2019s worth discussing what that treatment might cost \u2014 even if it is only in general terms. Certainly, readers of this release would be interested to know that the comparison drug, adalimumab (brand name Humira), costs almost $50,000/year. Considering the similarities between adalimumab and guselkumab, the release should have warned that if this experimental drug is approved, it might well also command a hefty price.", "answer": 0}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nThe journal supplement features seven papers authored by leading nutrition scientists that explore the state of the science pertaining to vegetable consumption in children.\nThe forum was supported by the Alliance for Potato Research and Education, a not-for-profit organization dedicated to expanding and translating scientific research into evidence-based policy and education initiatives that recognize the role of all forms of the potato--a nutritious vegetable--in promoting health for all age groups.\nThe executive summary \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is available online at http://advances.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. We won\u2019t penalize the release for not including this information since potatoes are a common and relatively inexpensive food. The release could have noted the average cost of a pound of potatoes to give parents a sense of how they might fit into a family grocery budget.", "answer": 2}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\nThe ICR chief executive, Prof Paul Workman, said the test could \u201cusher in a new era of precision medicine for prostate cancer\u201d.\nThe test, developed by researchers at the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS foundation trust, picks out men suitable for treatment with olaparib, part of a revolutionary class of drugs called \u201cPARP-inhibitors\u201d, which stops damaged cells from repairing themselves.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not mention costs.", "answer": 0}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no actual \u201ctreatment breakthrough\u201d in the data that needs a price tag. The implication is that less\u00a0treatment is acceptable, which should cost less. The release could have made this point but we won\u2019t penalize it for not doing so.", "answer": 2}, {"article": "Testing cholesterol in toddlers and babies?\nThe study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\nThe study also revealed parents who had the condition but didn\u2019t know it, and had passed it on to their children.\nStatins aren\u2019t recommended until around age 10, but certain dietary supplements such as plant sterols and stanols could help younger kids, Urbina said.\n\u201cIt\u2019s reasonable to screen for something that\u2019s common, dangerous and has a treatment that\u2019s effective and safe.\u201d\n\nDr. William Cooper, a pediatrics and preventive medicine professor at Vanderbilt University, called it \u201can innovative approach\u201d that finds not just kids at risk but also parents while they\u2019re still young enough to benefit from preventive treatment, such as cholesterol-lowering statin drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a strong point for the story, which did provide some information on cost. \u201cThe study did not address whether screening is cost-effective. In the U.S., cholesterol tests cost around $80 and usually are covered by health insurance, though much lower prices often are negotiated. The study authors in England estimated that if cholesterol testing costs $7 and gene testing costs $300, it would cost $2,900 for every person identified as having the disorder.\u201d We wish the story would have noted the cost of gene testing in the U.S. but otherwise found this satisfactory.\nThe story also could have noted that although statin drugs are generic and relatively inexpensive, the long-term costs of treatment from childhood onward are likely to be significant.", "answer": 1}, {"article": "For more information, visit www.chronothera.com.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nTest group subjects had nicotine administered over a 30-hour time period via Chrono's prototype device that delivered nicotine according to Chrono's \"peaks and troughs\" profile.\nChrono's first application is in smoking cessation, enabling smokers to overcome the world's deadliest addiction.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release fails to\u00a0mention costs, and for a condition such as smoking, which disproportionately affects lower income populations, cost is crucial. The news release is quick to discard the value in nicotine patches and gum, which are available for under $50 at most drugstores. A \u201ctransdermal drug delivery device\u201d would be much more expensive than the traditional methods. It wasn\u2019t easy to find a cost for the kit but in 2014 it was reported that the system would cost an individual between $400 and $500 for a 10-week course of therapy.", "answer": 0}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\nHowever, he cautioned that the high cost of rilonacept will most likely curtail its use.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This issue was discussed only vaguely.\nAn independent expert said that rilonacept was \u201cvery expensive\u201d and that \u201cinsurance will be an issue.\u201d\nIt\u2019s good that both issues were acknowledged.\u00a0 But the story also explains that the drug is already used to treat another disease \u2013 so costs could have been nailed down precisely.\u00a0 But they weren\u2019t.\u00a0 What does \u201cvery expensive\u201d mean?\nThe NY Times reported the cost to be about $5,000 a week in a 2008 story.\u00a0 That comes to a whopping $80,000 for a 16 week course. ", "answer": 0}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The news story provides no information on the costs of using these drugs or alternative medicines.", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to discuss costs. Given that this drug is apparently meant to be taken in addition to other drugs, it likely will result in an increased cost to patients who already are on medication.\nThe commercially available humanized monoclonal antibodies used to treat other diseases like rheumatoid arthritis can cost thousands of dollars per month and are frequently singled out by insurance companies for large copays.\nThis is important context that was left out.", "answer": 0}, {"article": "\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nShe said breast mammograms have contributed significantly to reducing deaths from breast cancer, a fact that should not be ignored in favor of mathematical models.\nHis team calculated that a woman who gets a yearly mammogram starting at age 40 cuts her risk of dying from breast cancer by 71 percent compared to a 23 percent reduction in risk if a woman followed the task force recommendations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The piece does not include any discussion of the financial, physical, or emotional costs of beginning routine mammography screening at age 40, which the authors of the new analysis see as necessary.\u00a0 The financial costs of overdiagnosis are significant for both the individual diagnosed and for society.\u00a0 The article does not include information about the increased number of false positives that will result from annual screening beginning at age 40 or about the significant physical and emotional costs of false positives.\u00a0 The article\u00a0is dismissive of these harms.\u00a0 From the article it is not clear whether the new analysis considered any of these harms or was solely based on breast cancer mortality.", "answer": 0}, {"article": "...\nMaryam Farvid, a fellow at the Harvard School of Public Health who is lead author of the study, says the influence of fiber on cancer risk may be time-sensitive.\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nShe says it can be hard to get the attention of teenagers about healthy eating.\nA Diet High In Fiber May Help Protect Against Breast Cancer\n\nIf the advice to eat more fiber seems easy to ignore, you're not alone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are a lot of foods you can eat to increase your dietary intake of fiber, and the story singles out fruits, vegetables, whole grains, beans, nuts and seeds. We\u2019ll rate the story Not Applicable since most people are aware of the cost of the foods mentioned. However, we wish the story had discussed the fact that many of these healthy sources of dietary fiber are either unaffordable or unavailable to many young women, particularly those from low-income backgrounds who live in food deserts. As we noted with the CBS story, we recognize that this is a story about breast cancer risk, not about food availability. However, if a story focuses on the importance of a healthy diet, there should ideally be at least a brief acknowledgment that many people do not have access to the foods that make up a healthy diet.", "answer": 2}, {"article": "Visit the American Heart Association for more on statins.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the cost of statins. While their use for cancer is only hypothetical, the story could have touched on how widely they are prescribed now and some cost information.", "answer": 0}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reported the drugs all cost about $600 a month and insurance is expected to offset the cost, \u201cbut patients will be eligible only if they have tried other drugs first and found they didn\u2019t help.\u201d", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\n\"The qualities of a good video game, things that hook you, what makes the brain \u2014 snap \u2014 engage and go, could be a perfect vessel for actually delivering medicine,\" he says.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\nBut, Ehlers still thinks game designers should go through the same FDA tests and trials as drug manufacturers.\nIt's a total switch in mission, from dreaming up best-sellers for the commercial market to designing games to treat mental health conditions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of the games. The story does quote an insurance industry executive who suggests that the\u00a0reimbursing patients to play games could lead to overall cost savings, but we didn\u2019t think that was quite enough for a Satisfactory rating.", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the two devices discussed each cost around $150,\u00a0a fairly steep price for a device that offers no clear evidence of an improvement in health.", "answer": 1}, {"article": "(Reuters Health) - When a migraine strikes, patients might one day be able to make the experience less painful by using a smartphone-controlled device to deliver mild electric shocks to their arm, a company-funded experiment suggests.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\nResearchers asked participants to put the device on their upper arm as soon as possible after the start of a migraine and use it for 20 minutes.\nIf the device works in larger trials and becomes widely available for migraine patients, it might offer an alternative for people who can\u2019t tolerate migraine drugs or an option patients could try in addition to medication when they don\u2019t get enough pain relief from drugs alone, Schoenen said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was one downside to the story: There\u2019s no information about the cost, either for the Nerivio Migra or\u00a0similar treatments. We found that Cefaly \u2014 a\u00a0TENS device that\u2019s FDA-approved\u00a0for use on the forehead \u2014 costs roughly $350, according to the company\u2019s website.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told that \"each visit runs a little over $800, and Dr. Sister recommends follow-up visits every four to six months.\"", "answer": 1}, {"article": "\u201cCytokines are an alarm system in the body,\u201d said Dr. Curtis.\n\u201cBeing able to rapidly identify a central nervous system disorder as infectious can be crucial in rapid response.\u201d\n\n\u201cIn addition, the test could distinguish viral from non-viral infections, a distinction that could spare a child with a viral infection from an unnecessary course of antibiotics, and tailor the care toward antiviral and supportive measures as needed,\u201d said Dr. Curtis.\nAdditionally, within the patients identified with central nervous system infections, the CSF cytokine fingerprint was different in cases of viral infection compared to those with non-viral pathogens, such as bacteria or fungi.\nRather than testing for the presence of bacteria or virus, the researchers looked at the first tell-tale signs of infection: the cytokines produced by the patient\u2019s immune system in response to pathogens and other injury processes.\nNow, researchers at Jefferson (Philadelphia University + Thomas Jefferson University) have developed a test that could rapidly parse out infections of the brain from other diseases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs for the test are mentioned, but a lumbar puncture can cost anywhere from about $600 to more than $2,000, with a \u201cfair price\u201d being about $1,000, according to Healthcare Bluebook. And this may or may not include the necessary laboratory work on the sample. (The cost of using a device called a Luminex FlexMap 3D assay, which is critical to the study, also isn\u2019t disclosed.)\nFor those with robust insurance plans, only a copay may be necessary. However, those with high-deductible or significant cost-sharing (or co-insurance) plans may be in for some sticker shock.\nIf offices and hospitals will be required to send test samples to specialized labs for analysis that could also impact the cost.", "answer": 0}, {"article": "FDNA scientists published a paper in January showing that their algorithm could better identify Down syndrome after being trained with a more diverse set of faces, and Muenke and Linguraru have also published papers this year demonstrating their algorithm\u2019s ability to identify genetic disorders correctly in children across a variety of ethnic backgrounds.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nMeanwhile, Muenke and his colleagues at the NIH last month published an important advance: the ability to diagnose disease in a non-Caucasian face.\nEventually, the software will also have to be able to tackle people with mixed ethnic backgrounds, too.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no prices in this story. Cost is critical, particularly as this is proposed as helpful in resource-poor settings.", "answer": 0}, {"article": "An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\nMillions of CoolSculpting treatments have been performed in more than 80 countries.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\nCoolSculpting is available through a network of CoolSculpting Centers worldwide.\nAllergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "According to CoolSculpting.com, the company estimates costs ranging between $2,000-$4,000, depending on the number of areas treated. Purely cosmetic procedures are typically not covered by insurance, unless you can make a case that it\u2019s \u201cmedically necessary\u201d (e.g. your droopy eyelids interferes with vision).\nSince costs are not discussed in this news release, we rate this one Not Satisfactory.", "answer": 0}, {"article": "When nicotine enters the body, it binds to the same receptors in the brain that acetylcholine binds to, resulting in smoking's rewarding and reinforcement effects.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release. Some mention of costs would have been useful and could have taken a number of different forms such as how the cost of these drugs would compare to buying cigarettes on a daily basis, comparing the drug price to other tools for quitting smoking, or providing cost estimates of treating smoking-related diseases.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. Given that calcium supplementation can last for decades, we think costs would have been important information and easy to access. Although calcium supplements are inexpensive for the individual, the amount of money in aggregate that is spent on supplements would be an important piece of context.\n", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nFurther, the protective association of seafood was even stronger among individuals with a common genotype (APOE-\u03b54) that increases the risk of developing Alzheimer's disease.\nPeople who ate more seafood had reduced rates of decline in the semantic memory, which is memory of verbal information.\nThe age-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t discussed. And because it\u2019s about a widely-consumed food that is a staple for many diets, we\u2019ll rate it not applicable. However, it\u2019s worth noting that seafood can be more expensive than many other types of food. What\u2019s more, since the story discusses seafood primarily as a vehicle for omega-3 fatty acids, cost becomes even more of an issue. And when it comes to omega-3 fatty acids, not all seafood is created equal. Salmon, for example, has a lot more omega-3 fatty acids than a similar serving size of catfish \u2014 but it\u2019s also a lot more expensive. There is also the issue of accessibility. People living in so-called \u201cfood deserts,\u201d which are often found in socioeconomically challenged areas, may have difficulty even reaching stores or restaurants that sell seafood.", "answer": 2}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\nGeneral support for Marb\u00e1n's laboratory is provided by the National Institutes of Health.\nThe study was published today by the European Heart Journal.\nCapricor has licensed the process from Johns Hopkins and from Cedars-Sinai for clinical and commercial development.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the potential cost of stem cell infusions generally or of CAP-1002.", "answer": 0}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nFor cancer prevention experts, the British study is provocative and significant.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss the cost of daily aspirin intake. Because the cost to individuals is low and well-known, we won\u2019t insist on this point. Nevertheless, were a recommendation made for everyone to begin taking aspirin daily starting at age 45 the national price tag would be substantial. Readers would also benefit from an acknowledgement that such a recommendation would lead to higher spending on treatment of bleeding ulcers and other adverse events that would offset some of the potential cancer-related savings.", "answer": 2}, {"article": "Cytology-based screening, known as the Pap test or Pap smear, is used to detect abnormal cells.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nGiven the rarity of cancers among screened women, the contribution of the Pap test to screening translated to earlier detection of at most five cases per million women per year.\nThe accumulated evidence supports inclusion of HPV testing in screening; thus, the main choice moving forward is between cotesting and primary HPV testing alone.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release includes the idea of costs, but without using any numbers. The two mentions of cost are here:\n\u201cHowever, reports of rare HPV-negative, Pap-test positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\u201d\nand here:\n\u201cResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\u201d\nThe readers are not given any framework in which to judge how much more co-testing may cost than single-testing by either of the methods discussed. We are also not given any society-wide idea of what we all might save if both tests were not routinely administered.", "answer": 0}, {"article": "Read all the details of this study, the full list of contributors and their financial support in Clinical Cancer Research.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\nFurthermore, these tumor cells were sensitive to an experimental drug, neratinib.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\n\"A circulating tumor DNA-based blood test also could therefore be potentially used to monitor tumor progression and to determine whether patients are responding or not to treatment after just one month of therapy,\" Ellis said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost in this release. Neratinib (marketed as Nerlynx) was approved July 17, 2017 for the treatment of early-stage HER2+ breast cancer so cost estimates should be available.", "answer": 0}, {"article": "She said the findings are important because, \"they help us understand why individuals with autism have difficulty with complex behaviors, such as social interaction and language.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\nThe children with autism also had increased connectivity between brain regions that were farther apart, which might be a mechanism developed to compensate for reduced short range connectivity, the researchers said.\n\"This reduced functional connectivity in the brain helps us understand impairments associated with autism,\" she added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the study, even though EEGs have been in use for more than 60 years.", "answer": 0}, {"article": "The children were instructed to do an hour per day of near-vision activities such as homework or computer work.\n''Acupuncture could potentially become an alternative treatment to occlusion [patching] therapy for ambylopia [lazy eye], the researchers write.\nAt 15 weeks, visual acuity with eyeglasses improved by about 1.8 lines on the vision chart in the patched eyes and 2.3 lines in those who had acupuncture.\nDec. 13, 2010 -- Acupuncture treatments to treat one type of lazy eye proved as good as the traditional patching of the eye used to help the eyes work together, according to a new study.\nThey assigned 43 children to the acupuncture group, and they received five treatments a week.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A source in this story cited time and expense as two factors that might decrease the attractiveness and accessibility of acupuncture. However, it never\u00a0attached figures to these concerns. We think the story should at least have mentioned\u00a0the cost of a typical office visit\u00a0to an acupuncturist.", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\nBetween 10 percent and 15 percent of autism cases can be traced to a known genetic cause, the researchers noted.\nCMA detected chromosomal abnormalities in slightly more than 7 percent of patients, making it the best available genetic test for autism spectrum disorders, the study authors said.\nStandard practice is to offer children with autism two tests as a first-line genetic work-up: karyotype and fragile X testing, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention specific costs of the CMA test; however, it did indicate that not all insurance will cover this test. Since the story stated that\u00a0 \"both Children\u2019s Hospital Boston and Montefiore have offered CMA testing for several years,\" some cost estimate could have easily been found. ", "answer": 0}, {"article": "\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nIt could be several more years before the patch will be available for consumers.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nFor those plagued with peanut allergies, protection may eventually come in the form of a patch worn on the skin, a new study suggests.\nThe skin patch \u2014 intended to desensitize patients to peanuts by exposing them to tiny amounts of the allergen \u2014 may be particularly appealing to children who are too frightened to try oral or under-the-tongue therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no effort to describe the likely cost of this \u201cpeanut patch\u201d intervention. Even if a precise number can\u2019t be provided, are we talking tens, hundreds, or thousands of dollars for treatment? Some estimate should be possible at this stage of development.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nDoctors usually can\u2019t predict whether a man will suffer all or none of those side effects.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nThe more of the 12 a man had, the greater his chances of radiation therapy complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not addressed. Genomic analyses, although becoming cheaper, still may cost around $1000.", "answer": 0}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nPhentermine is not recommended for use in pediatric patients 16 years of age or younger.\nThese are not all of the potential side effects of phentermine.\nThese are not all of the potential side effects of phentermine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release makes the specific point that this newly approved dosage of the drug Lomaira (phentermine hydrochloride USP) will cost eligible patients \u201cno more than 50\u00a2 per tablet for the duration of treatment\u201d if they qualify for the manufacturer\u2019s assistance program. It makes the point that many insurance plans will not cover the cost of weight management drugs and that the low cost of this formulation should aid those who are prescribed it. The low-cost aspect of the drug is mentioned in both the headline and in the\u00a0first paragraph of the release. The release would have been stronger had it mentioned the basic cost of the drug, regardless of any manufacturer\u2019s qualifying discount.", "answer": 1}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\n\"This means patients with large stones might not need more complicated treatments including surgeries, and this has potential to improve care and reduce costs.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives a brief nod to costs when it quotes the lead author stating \u201cthis has potential to improve care and reduce costs,\u201d but it goes no further. There is no mention of the cost of tamsulosin, nor the length of time patients might need to take it to relieve kidney stones.", "answer": 0}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\nThe team further observed that people who ate baked or broiled fish weekly displayed better so-called \"working memory,\" enabling them to more effectively execute routine tasks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish in the diet wasn\u2019t discussed but we trust most people have a general idea of those costs.\n ", "answer": 2}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nAccording to McEvoy, doctors should focus on patients\u2019 lifestyle and traditional risk factors such as smoking and obesity.\nHis team looked at 1,000 Korean patients who chose to get a heart scan as part of a health screening program at Seoul National University Bundang Hospital.\nMore than a fifth of the patients who got scanned had cholesterol buildups in their arteries, also called atherosclerosis.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were reported.", "answer": 1}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\nMolina noted that antibiotic resistance to doxycycline has not been seen in chlamydia or syphilis, despite the fact that the drug has been used to treat these infections for decades.\nMolina insisted he would never support long-term use of antibiotics to prevent STIs, but said that the approach might be an effective short-term strategy when paired with other control approaches, like more frequent STI testing among high-risk populations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of preventative use of doxycycline. Based on the average use in this study of about seven pills per month, the cost of the drug might be about $30/month. But that cost does not include regular lab testing, which the study authors said should be mandatory in this sort of high-risk group. The cost of clinic visits also was not addressed in the story. Even though doxycycline is not an expensive drug by itself, any plan for widespread, routine use would entail much more than just paying for pills. We also think it would be interesting to consider the cost-effectiveness\u2013does the reduced disease burden reduce costs, too?", "answer": 0}, {"article": "An experimental Alzheimer\u2019s drug showed positive results and raised hopes anew that pharmaceutical companies were moving closer to a medicine that could finally disrupt the disease\u2019s memory-robbing course, though a string of failures shadow the efforts.\n\nAlzheimer\u2019s has proved an especially tough drug target. Approved therapies only relieve symptoms temporarily, and one experimental treatment after another promising to stymie the neurodegeneration has ultimately failed to work. Some pharmaceutical companies, after costly failures,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story frames the discussion in terms of income to the company, but doesn\u2019t address the costs to patients or society. The story said the estimated market for a drug that could alter the course of Alzheimer\u2019s \u201ccould be worth more than $10 billion in yearly sales.\u201d\nSome discussion of the cost to society of treating Alzheimer\u2019s would have been a good addition. Or, the story could have explored the cost per patient using the potential revenue estimates to give readers a sense of how much a drug like this might cost.", "answer": 1}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n\"Because Nathalie had previously shown that parvalbumin passes into the body of the person eating fish, it made sense to study its interaction with human proteins.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Affordability of fish varies widely around the world so we can understand not bringing up costs.\nThe intervention advocated is consuming a fish protein called parvalbumin, or PV for short. Some readers may be curious if this protein can be found in the fish oils that are widely marketed. Nonetheless, the issue of cost doesn\u2019t seem entirely applicable here.", "answer": 2}, {"article": "For more about multiple sclerosis, visit the National Multiple Sclerosis Society.\n\"Although alemtuzumab [Lemtrada] treatment is associated with safety risks, those risks are manageable in most patients,\" Miskin said.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nLemtrada is not for every patient with MS and the decision to use it should be carefully considered, said Dr. Dhanashri Miskin, an attending neurologist at Lenox Hill Hospital in New York City.\n\"Although the safety profile is generally manageable for the right patient, risks probably outweigh benefits in patients with mild or early stage disease,\" Miskin said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs,\u00a0which we consider a major oversight.\u00a0As a Boston Globe story explains: \u201cGenzyme executives said Lemtrada will be priced at $158,000 for two courses of treatment over two years.\u201d\nFor MS patients, this enormous price tag was a major point of discussion when the drug was first approved. \u201cMy excitement for Lemtrada\u2019s possibilities as a treatment that brings us close to a cure for MS is dampened by the super inflated drug charges of 900% for each vial of alemtuzamab,\u201d wrote\u00a0Laura Kolaczkowski\u00a0in a piece looking at the economics of this drug.", "answer": 0}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nClinical trials for that treatment are now underway.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We think that costs should almost always be part of a discussion for a new treatment and this brief report is no exception. Autologous stem cell transplants, performed for certain types of cancer, can cost in excess of $100,000. Since the procedure is experimental, as noted in the story, it is not likely to be covered by insurance.", "answer": 0}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nAs for cost, she said that a month's supply of similar ginger supplements typically runs about $10 to $30.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that a month\u2019s supply of ginger supplements typically runs about $10 \u2013 $30.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\nThe test has also shown promise in predicting which patients with mild memory loss are at high risk of developing the dreaded syndrome, which each year kills 66,000 Americans and inflicts incalculable heartache on the families of its victims.\nBut he said that a test showing the likelihood that the disease will develop will help patients and family members prepare for what lies ahead.\nMucke acknowledged that there are very few medical treatments for patients once they are diagnosed with Alzheimer's.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Potential costs not addressed.\u00a0 However, this is not a commercially available test or even available in most research labs so costs are very difficult to predict.\u00a0 But a story like this also could have touched on the whole issue of the downstream costs associated with testing everyone who forgets someone\u2019s name or where they put their car keys \u2013 could be enormous \u2013 and the costs of providing what are now relatively ineffective current drug treaments.\u00a0\u00a0\u00a0 ", "answer": 2}, {"article": "UCH-L1 is released by brain nerves when they\u2019re stressed, and its levels rise more rapidly immediately after injury and peak at eight hours.\nMORE: A New Blood Test to Diagnose Concussions On The Field\n\nIn the emergency room, a blood test for UCH-L1 could also help doctors decide which patients should get a CT scan \u2014 the higher their levels of the protein are, the more likely they are to have TBI and would benefit from a scan, while those with lower levels probably don\u2019t need one.\nAnd because levels of GFAP tend to remain higher for many days, Papa says it might be useful in cases where patients don\u2019t come in immediately after a head injury, thinking they\u2019re okay, but see the doctor several days later because they\u2019re concerned.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\n\u201cI don\u2019t think a blood will be the be-all and end-all but it would be a beautiful tool for us to have in the clinic to support a lot of our decision making.\u201d\n\nTesting for levels of UCH-L1, for example, might be helpful for emergency medical teams in an ambulance trying to assess whether a patient has any serious head injuries, since its levels peak in the hours immediately after a trauma.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed here. But readers should be informed if there are commercially available tests for the proteins the researchers were measuring, and how much they cost. If not, the costs of tests for similar proteins could possibly be used to give a ballpark estimate.", "answer": 0}, {"article": "\"There was no significant difference,\" Boden said.\nAlthough about one-third of patients who initially got medical treatment later turned to angioplasty, the findings show how much medical treatment of heart disease has improved, Boden said.\nThe findings underscore the danger of rushing to adopt a procedure before careful studies have been conducted to fully determine its benefits, Boden and others said.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that angioplasty typically costs $50,000.\u00a0 While it would have been helpful to have a sense for the cost of angioplasty in in comparison to medical therapy, the story does give a sense of the cost burden to the healthcare system by providing procedures that don't benefit a significant proportion of patients.\u00a0 ", "answer": 1}, {"article": "The surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\nYet the cases were judged to be a success because the seizures decreased in frequency over time.\nRather than pay $35,000 to $50,000 on surgery that might cure the problem and prevent further damage to the child, insurance companies prefer to demand that more drugs be tried, even if the odds of them working in drug-resistant cases is small, he said.\n\u201cThe study in kids shows if you reduce the time from the onset of seizures from the 15 to 20 years you see in adults down to four to five years, the outcome is much better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does an outstanding job of noting the cost of surgery, although the article could have been stronger if it had pointed out the estimated costs of drug therapies, hospitalizations and sometimes institutionalization of children and adults who are severely disabled by some forms of seizure disorders.", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A company official declines to estimate how much the test will cost. This information is in the last line of the story.\u00a0\nIt\u2019s tempting to assign a satisfactory rating for at least asking the question.\u00a0 \nBut a more complete story would have asked the official to estimate a price compared to the company\u2019s similar breast cancer test now on the market. \nIn fact, one did: A Bloomberg story reported that the company\u2019s breast cancer test costs about $3,800. \nAn even more complete story, from the Associated Press, mentioned that despite their price insurers often pay for some tests like this because they may be able to avoid spending $30,000 to $40,000 for chemotherapy on patients who do not benefit.\u00a0 \nReporting costs is important for at least two reasons:\u00a0 ", "answer": 0}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nIn the meantime, she pointed out, a woman walking through a clinic door who is diagnosed with triple-negative breast cancer shouldn't panic.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nThis means that many currently available drugs simply won't affect it.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the potential cost of the drug.\u00a0 Since the story briefly discusses \u201ca similar drug\u201d it could have at least given the cost of that drug.\u00a0 As it is, cost is unaddressed \u2013 a huge vacuum.", "answer": 0}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nWhen they took leptin, their calorie burning increased to pre-diet levels.\nAnd the leptin study suggests that the weight loss solution may eventually be a pill that tricks the brain into thinking that no weight has been lost.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nThen, for five weeks, they were given twice-daily injections with enough leptin to restore the levels they had before losing the weight.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of possible costs \nfor leptin; no mention of costs of other methods of weight maintenance.", "answer": 0}, {"article": ".\nOn another night, the windows and door to the room were kept closed.\nOverall, skin temperature and the bed temperature were higher in closed conditions than open conditions.\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\nIn the meantime, Mishra and colleagues monitored carbon dioxide levels, temperature, background noise and humidity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The opening of windows and doors has no cost.", "answer": 2}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the physician-expert interviewed for the article works at an academic medical center\u2013where there is conceivably a vested interest in root-cause and advanced immunotherapies instead of OTC symptomatic care\u2013the article deserves gold stars for noting the costs of the newer sublingual tablet and drop treatments, and some important information about what most insurers will and won\u2019t cover. Ideally, the article would have also mentioned the costs of over-the-counter options to provide a comparison point.", "answer": 1}, {"article": "Traditionally, dentists were taught that the only way to deal with decay was to drill it out.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nThat's still important in some cases, Featherstone says, but without fixing the underlying problem of bad bacteria, patients just keep coming back for more fillings.\nHe recently published a study that found using these techniques reduced the need for fillings in adults by 30 to 50 percent.\nWhen Featherstone put his patients on personal treatment plans, he found the strategy worked.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does include a discussion of price, reporting that a fluoride varnish treatment can cost $23 to $55, while a filling can cost $86 to $606. That\u2019s enough to be rated Satisfactory.\nHowever, the story also should have stated that those numbers aren\u2019t a head-to-head comparison, since the varnish treatment must be repeated many times over many years\u2013which would add up. In fact,\u00a0a cost-effectiveness analysis done by one of the quoted experts concluded the \u201cCaries Management System\u201d he advocates costs almost $1,800 for every cavity or lost tooth prevented.", "answer": 1}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story alluded to the fact that patients would have to pay to have a test done correctly. Even better would have been an actual cost for the test, or range of possible costs.", "answer": 0}, {"article": "Collaborating with Dr. Pisco were Marisa Duarte, M.D., Tiago Bilhim, M.D., Ph.D., Jorge Branco, M.D., Ph.D., Fernando Cirurgi\u00e3o, M.D., Marcela Forjaz, M.D., L\u00facia Fernandes, M.D., Jos\u00e9 Pereira, M.D., Nuno Costa, M.D., Joana B. M. Pisco, M.D., and Ant\u00f3nio G. Oliveira, M.D., Ph.D.\n\nRadiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc. (http://pubs. )\nThe procedures had a clinical success rate of approximately 79 percent for fibroid-related symptoms.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\nHowever, myomectomy is not always possible or effective and can result in major complications including hysterectomy, according to study co-author Jo\u00e3o Martins Pisco, M.D., Ph.D., from the Department of Interventional Radiology at Saint Louis Hospital in Lisbon, Portugal.\nSuch patients have a fibroid recurrence rate of more than 60 percent after myomectomy, making UFE an important option.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The costs of the three treatments considered \u2014 conventional UFE, partial UFE, myomectomy \u2014 are\u00a0not discussed in the news release.", "answer": 0}, {"article": "Obesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nResearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does a good job here, comparing the average cost of three different procedures: \u201cresearchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\u201d However, the release also notes that banding and gastrectomy involve spending more time in the hospital, and it\u2019s not clear if those costs are solely for the procedures, or if they are for both the procedures and the hospital stay. Some clarification there would have been valuable.", "answer": 1}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\nThey suggested a number of steps people can take to improve their level of optimism.\n\u201cOptimism in prior research has been shown to be related to better health behaviors and better health outcomes, particularly in cardiovascular disease,\u201d postdoctoral research fellow Kaitlin Hagan, co-lead author of the study, told CBS News.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Optimism is free of charge, and anyone who says differently is overly optimistic about stealing your money.", "answer": 2}, {"article": "PSA tests are used to screen men for prostate cancer, but they're imprecise.\nThe work is \"another step on the road to more sophisticated\" prostate cancer screening and treatment, Dr. Timothy Church of the University of Minnesota wrote in an editorial accompanying the work.\nThe study is far from proof that making health decisions based on so-called PSA velocity can really save lives.\nYet routinely biopsying men with low PSA would worsen another problem, overdiagnosis.\nAnd men diagnosed with prostate cancer whose PSA is rising slowly may be ideal candidates for monitoring instead of surgery or other treatment, he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs of PSA testing (or the number of tests over what period of time are\u00a0needed to determine PSA velocity).\u00a0 ", "answer": 0}, {"article": "\"This is not ready for prime time,\" he said.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\nIt's \"much too early\" for patients or caregivers to seek out DBS, said Fargo, who was not involved in the study.\nFor caregivers, Fargo said, the problems with abilities like judgment and planning can actually be more challenging.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t talk about the cost of this device. Deep brain stimulation surgery for Parkinson\u2019s disease costs $35,000 to $50,000, according to the National Parkinson Foundation.", "answer": 0}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nThe study was funded by Johnson & Johnson, which is developing the drug.\nThis study was presented at a medical conference.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 The competing Wall Street Journal story, by comparison, reported:\u00a0\"Cost could be a factor. The three-treatment Provenge regimen has been controversial partly because of the $93,000 cost. Dendreon has said treatment costs are comparable with chemotherapy if total costs of care are taken into account.\"", "answer": 0}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\n\"At present the only way to diagnose esophageal cancer or stomach cancer is with endoscopy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a tough call, since this is early research. But heeding our mantra \u201cif it\u2019s not too early to talk about benefits, then it\u2019s not too early to talk about costs,\u201d an estimate would be useful here.", "answer": 0}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\nThe pleased mother of three in the news clip said her breasts grew \u201covernight,\u201d which is misleading.\n\u201cI didn\u2019t have to put anything foreign in my body.\u201d\n\nAt the October meeting of the American Society of Plastic Surgeons, Dr. Khouri presented a long-term study that suggested liposuctioned fat was now a \u201cviable alternative to breast implants.\u201d It tracked 50 women, ages 17 to 63, for an average follow-up of 3.5 years.\nNor has \u201cconcentrating\u201d cells in fat been proved to make a difference in controlled studies, said Dr. Karol A. Gutowski, chairman of the plastic-surgery society\u2019s task force.\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says that breast augmentation using fat grafts is usually more expensive than implants, but it does not include any price range for either type of procedure.", "answer": 0}, {"article": "Research has shown that our unhealthy eating habits and sedentary lifestyles are playing a major role in the development of lifestyle-related metabolic diseases such as diabetes, heart disease and obesity.\nThe fasting regime helped lower fat build-up in the white fat by increasing the brown-like fat (involved in burning energy and producing body heat) of mice on the high fat diet.\nThe research team in this study wanted to better understand the reactions that interventions such as fasting trigger on a molecular level in the body.\nThe lower body weight of the mice in the fasting group was not the only effect.\nThe recurring regimen saw the animals being fed for two days, followed by one day without anything to eat.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss costs of the mice chow used in the study but we\u2019ll still rate this Not Applicable since our emphasis is on human interventions. People wanting to embark on a semi-fasting program could do so without purchasing any products.", "answer": 2}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost not discussed but since the article clearly stated that the methods discussed are \u201cat least years away,\u201d this is understandable.", "answer": 2}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nBut a separate finding about the effect of the drug on death risk was a surprise.\nThe results were part of the Early Breast Cancer Trialists' Collaborative Group, a collaboration based at the University of Oxford, that collects and analyzes information about randomized clinical trials every few years.\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\n\u201cThe drugs are complementary, because the main side effect of aromatase inhibitors is an increase in bone loss and fractures, while bisphosphonates reduce bone loss and fractures as well as improving survival,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Washington Post article calls aromatase inhibitors \u201cinexpensive,\u201d but it doesn\u2019t put a price tag on them. According to some reports, patient copays for taxomifen and aromatase inhibitors are around $8 \u2013 $9 for a month\u2019s supply of each drug, which we\u2019ll agree is inexpensive. But the cost of bisphosphonates is not addressed. We\u2019ll give the benefit of the doubt here for the story\u2019s nod in the direction of costs, but ideally we\u2019d prefer to see more specifics.", "answer": 1}, {"article": "Tobacco kills one-third to one-half of those who smoke.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention the cost of metformin, which is relatively cheap as a generic, thus adding to the potential appeal of this approach.\u00a0 This should have been mentioned. ", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOf that group, 85 percent had small tumors that had not spread.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nWhat it will take to prove that CAT scans are either useful or a waste of time and money is a matter of great controversy.\nOnly 15 percent of people with the disease survive five years from the time it is diagnosed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of the test. Since most costs will be covered by the patient and not by the\u00a0insurance company, this is vital information for the consumer.", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nSince then, doctors have prescribed ketamine \"off label\" to thousands of depressed patients who don't respond to other drugs.\nKetamine may also offer new hope for people like James who have symptoms of several different psychiatric disorders.\nMeanwhile, doctors have begun trying ketamine on patients with a wide range of psychiatric disorders other than depression.\nAnd it may also explain why ketamine helps people who have symptoms associated with several different psychiatric disorders.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss cost, even though it presents a substantial barrier to people who might want to explore ketamine treatment, especially since it is unlikely to be covered by insurance. Although ketamine is not approved by the FDA specifically for treatment of psychiatric diagnoses, some physicians do prescribe it. Some online sources quote costs of $400-800 per treatment (here and here). Typical treatment regimens involve multiple treatments at first, then maintenance sessions every few weeks. Most clinics inject or infuse ketamine. A nasal spray form is offered by some clinics, including this one, which charges $395 for an initial assessment, then $250 to $350 per session.", "answer": 0}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\nA treatment that improves the lives of nearly 1.3 million people with rheumatoid arthritis might one day originate from scorpion venom.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how much a product like this might cost or how the cost might compare with other treatments. Peptides International (funders of the study) lists iberiotoxin at $295 per 0.1 ml vial on its website.\u00a0 However, we\u2019re never told how much toxin is used when applied as a treatment so it\u2019s impossible to estimate what costs for a patient might run.", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included prices for several of the products described.", "answer": 1}, {"article": "Particularly fast increases have occurred among people older than 65 and among women 15 to 39 years old.\nTo be sure, more than half of patients with metastatic melanoma would not be helped all that much by either drug.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\nIn the trial, sponsored by Roche and led by Dr. Paul B. Chapman of the Memorial Sloan-Kettering Cancer Center in New York, 38 percent of participants had to stop taking the drug or lower the dose because of side effects, including rash and joint pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The significant costs of both drugs were mentioned.\u00a0 Nice job.", "answer": 1}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\nTurns out there\u2019s a simple blood test that could tell her.\nShe\u2019s grateful to the Baby Deadline Test for giving her that option.\nFor Alyssa Gold, the AMH test was a wakeup call.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re giving this a Satisfactory rating since the story did mention that the test \u201cusually costs less than $100.\u201d\nThe story would have been stronger if it had explained if insurance companies typically cover the test\u2013especially if it\u2019s being given to women without any history of infertility. There also may be associated costs with follow-up testing.", "answer": 1}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more about vaccines.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, but that seems like a minor issue in this context, so we\u2019ll grade this Not Applicable.", "answer": 2}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\n\u201cSince this surgery I\u2019ve actually had another disc herniate, complicating everything.\nJay says she was lucky: Her insurance covered much of the six-figure bill for the procedure.\nA next-generation implant deep in Jay\u2019s back stimulates her spinal cord, overriding her body\u2019s pain signals to give her some relief from the back pain that has plagued her for years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story scrapes by on this one \u2014 it said the surgery is \u201cexpensive\u201d and that Jay\u2019s insurance \u201ccovered much of the six-figure bill for the procedure.\u201d The story could have mentioned other costs associated with treating this condition. ", "answer": 1}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nHealth care providers should also evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Siliq.\nSiliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We rate this one Not Applicable.\nHowever, it looks like Siliq will end up being an expensive drug. Its main competitors could be Novartis\u2019 Cosentyx and Eli Lilly\u2019s Taltz \u2014 both of which cost thousands of dollars for a dose. A half dose of Cosentyx sells for over $8,300, while a half dose of Taltz costs over $13,600. Each drug then follows a different dosage pattern.\nIf companies can talk about a drug\u2019s benefits, then it\u2019s not too early to discuss what it may cost. We hope the FDA could one day also comment on the projected cost of a drug and its cost-effectiveness.", "answer": 2}, {"article": "Hysterectomy is the surgical removal of the uterus.\nWhat's happening now is that the vast majority, about 70 percent, are done the old-fashioned way, with a large surgical incision, lots of pain, and a six-to-eight-week recovery.\nThe surgery she's upset about may be archaic - but it's very common.\n\"You would want them to have the least invasive procedure possible.\"\n\"I'm outraged that doctors are still, in my mind, doing these archaic surgeries on people; we're opening them up unnecessarily,\" Warren said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story theorizes that the cost of laparoscopic surgery would be less than\u00a0abdominal hysterectomy because of the reduced hospital stay, no further information is provided. This is not adequate information on costs. Furthermore, there are even cheaper non-surgical alternatives such as medication, IUD, and ablation.", "answer": 0}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The companies competing to bring this therapy to market have not said how much they will charge. The story\u00a0acknowledges cost this way:\n\u201cCompany officials would not say what the treatment might cost, but other types of immune system therapies have been very expensive.\u201d\nThis is a barely passing satisfactory. Other news sources have brought up\u00a0that, since CAR-T cell therapy is an individualized gene therapy, the cost may run into the hundreds of thousands of dollars per patient.", "answer": 1}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nThe new research was led by Dr. Chirag Shah and Dr. Jeffrey Heier of Ophthalmic Consultants of Boston.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs for this procedure\u00a0in this story.\u00a0 Nor is there any indication whether most health insurance plans would cover such procedures.\u00a0 A quick search on the web suggests that the costs may run from several hundred dollars to several thousand dollars per eye, with no assurance that multiple treatments might not be required, raising the costs even more.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\nThe treatment and the placebo arms reported similar proportion of side effects, with one patient on the 6 mg/kg dose dying following excessive bleeding, J&J said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed. This is problematic given that Stelara is already on the market for use in treating other medical conditions \u2014 and it can cost thousands of dollars. The story also doesn\u2019t make clear that patients in the relevant trials received only a single dose (at one of two different dosages) \u2014 which is an important factor when considering cost.", "answer": 0}, {"article": "The oldest cyclists had less muscular power and mass than those in their 50s and early 60s and considerably lower overall aerobic capacities.\nThe findings suggest that many of our expectations about the inevitability of physical decline with advancing years may be incorrect and that how we age is, to a large degree, up to us.\nOn almost all measures, their physical functioning remained fairly stable across the decades and was much closer to that of young adults than of people their age.\nSome aspects of aging did, however, prove to be ineluctable.\nBut even so, both of those measures were higher among the oldest cyclists than would be considered average among people aged 70 or above.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s difficult for many people to be active as cyclists, especially in low-income areas that lack bicycle paths. It\u2019s also difficult for many to afford to spend the time needed to exercise. The story notes that older people today tend to be \u201cquite sedentary.\u201d Perhaps cost is a contributing factor.", "answer": 0}, {"article": ".\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nThe study is being published online in Menopause, the journal of The North American Menopause Society (NAMS).\nThe study showed electro-acupuncture to be comparable to, if not better than, gabapentin in helping to reduce hot flash severity and frequency and improving overall sleep quality (including falling asleep faster and fewer sleep disruptions).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention in the release as to the cost of electro-acupuncture, although a quick search on the web revealed that the costs per session could range anywhere from $60 to $150.\u00a0 Nor did the release give any information about the number of sessions required to acheive improved sleep \u2014 a single one or multiple.\u00a0 Lastly, the release gives no indication whether Medicare or health insurance plan will cover electro-acupuncture, a factor that can affect whether many patients would choose this treatment.", "answer": 0}, {"article": "\u201cWe had hoped to identify some of the characteristics of the women who benefitted from acupuncture, but like so many treatments, we could not really tell ahead of time who would benefit,\u201d Avis said.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nForty-seven percent of the study group reported a 47 percent reduction over this same time frame.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed at all. How much does it cost? And could acupuncture be covered by insurance? According to an acupuncture referral site, a single session of acupuncture typically costs between $60 and $120. Given that participants in this study received up to 20 acupuncture sessions over six months, that could present a significant financial hurdle for patients \u2014 particularly if they are paying for those sessions out of pocket.", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of Actos or other diabetes drugs.", "answer": 0}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\nThe Virginia Piper Cancer Institute\u00ae, part of Allina Health, provides comprehensive care through all aspects of cancer prevention, early detection and treatment to help individuals maintain quality of life and find ways to live with and beyond cancer.\nThe Institute was founded in 1990 at Abbott Northwestern Hospital.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of sentinel lymph node biopsy is not included in the release. Depending on the type of biopsy performed, costs can range from a few hundred dollars to several thousand.", "answer": 0}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\nAuthors analyzed 53 randomized controlled trials that examined knee OA treatments for at least 28 days and included a minimum of 30 participants per study group.\nAccording to a network meta-analysis research article published in the May 1, 2018 issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the nonsteroidal anti-inflammatory drug (NSAID) naproxen was ranked most effective in individual knee OA treatment for improving both pain and function, and is considered a relatively safe and low-cost treatment method.\nThe treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the news release does refer to the low-cost of naproxen (brand names including Aleve and Naprosyn), it does not discuss the costs of other treatments that were ranked highly by this meta-analysis. Injections of corticosteroids may cost about $100, not including associated clinic and provider charges. All of the treatments need to be repeated, so the cumulative cost should be considered.", "answer": 0}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that there was no cost to patients in this experimental group. The story gave no estimate of what the procedure might cost outside a clinical trial, however, the reporter made an attempt to get a cost estimate from the company, which declined comment. ", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unlike the HealthDay story, this one mentions cost. It says that the drug in question, Fosamax, \u201ccosts around $10 per month in the U.S.\u201d\nAlthough, of course, the real cost effectiveness would be determining costs in a population that had routine current screening plus the medicine. Then one could determine the relative benefits in terms of decreased cancer and the attendant costs of treatment.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\nLead investigator Prof Peter Goadsby, from King\u2019s College hospital, London, said: \u201cStrive \u2026 represents an incredibly important step forward for migraine understanding and migraine treatment.\u201d\n\nThe findings, reported in the New England Journal of Medicine, clearly showed that blocking the CGRP pathway could reduce the impact of migraine, he said.\n\u201cPlacebo responses [in migraine studies] are quite high and I think that is partly due to the subjective nature of pain and because of the strong psychological effects that being treated have on that experience of pain and those symptoms,\u201d he said, adding that injections generally result in an even stronger placebo effect than tablets.\nThe trial, called Strive, compared patients taking erenumab for six months with others given a non-active placebo dummy drug.\nCader said that he too was looking at running trials using antibodies, and said he was excited about the approach since it might result in fewer side effects than current therapies, and would mean individuals would not have to remember to take a table every day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost estimates are provided. \u00a0But cost is a big deal with this drug. According to a November 2016 story by The Verge, erenumab could cost $8,000-$20,000 a year \u2014 or about $667-$1,667 per monthly injection. \u00a0We understand that this story originated in the UK, where perhaps there\u2019s a different journalistic attitude about the importance of citing costs because the UK has a National Health Service, unlike the US. But this story appeared in the US edition of the Guardian, so big deal cost estimates matter.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nThe goal is to help the concussion patient feel better as the brain heals.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\nThere was no funding used for this study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release.", "answer": 0}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nThe device alone reduced that to about one seizure a year.\nThe approach, which is not yet approved by the FDA, could offer an alternative or enhancement to treatment with drugs, says Christopher DeGiorgio, the neurologist at UCLA who invented the new approach.\nAnd the trigeminal nerve stimulator is not the first time researchers have used electrical pulses to prevent seizures.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. There are similar devices in use, including one for epilepsy that is mentioned in the online story. Cost information should have been provided, at a minimum, for one of those devices.", "answer": 0}, {"article": "\"Perhaps most importantly reducing pain medication use.\"\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nSaper says yoga likely works by strengthening core and lower back muscles and helping with mind-body relaxation.\nNEW YORK -- A new study says yoga may be as good a treatment for back pain as physical therapy.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of a set of yoga classes for a patient with chronic back pain. It would also be helpful to talk about whether insurers would reimburse patients for yoga in the same way they reimburse for prescription pain medications. Out of pocket costs may be greater for yoga than for PT, which may be more likely to be covered by the insurer.", "answer": 0}, {"article": "\u201cI think that\u2019s important because it paves the way for potentially studying patients without chronic pain and offering the treatment sometime in the future to reduce blood pressure,\u201d he says.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\nThe case study is published in the Jan. 25 issue of Neurology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2013 a major omission. According to one estimate our reviewer accessed within minutes, costs for the device and procedure may be upward of $150,000 per patient. Any discussion of costs should also include the costs required to monitor the device over time.", "answer": 0}, {"article": "Normally, cells in the pancreas work to release insulin, a hormone that can process sugar and either send it to cells that need it for energy or store it as fat for future energy needs.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nAll of the people had been diagnosed with type 2 diabetes in the six years preceding the study.\nTaylor and his team tracked outcomes including weight loss, diabetes remission and level of fat in the pancreas and liver.\nAfter a year, most of the people in the diet group lost about 22 pounds, compared to two pounds in the control group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs, although the diet intervention included weeks of a liquid formula diet, along with support services such as nutritional education and cognitive behavioral therapy.", "answer": 0}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nIn the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company.\nSimilar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price tag of this new treatment is the focus of this article. The story also discusses the models of treatment proposed by the manufacturer.\u00a0 Well done.\nTwo things, though: It wasn\u2019t clear from the story if the patients in the trial had both eyes treated, which would make the more accurate price tag $850,000 vs the talking point of \u201c$425,000 per eye.\u201d\nAnd does this cost include everything\u2013surgical care costs (operating room, anesthesia, etc), physician payments, and lab costs?", "answer": 1}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nBut many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection.\nBy doing both, the ability of imaging to accurately plot a tumor\u2019s location is increased and there is a more refined sense of the tumor\u2019s extent, said Nathan White, PhD, assistant project scientist at UC San Diego, study co-author and co-inventor of the RSI-MRI technique.\nIn a related paper to be published in the journal Frontiers in Oncology, the same team of researchers reported that RSI-MRI appears to predict tumor grade.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It is unclear if this MRI method is more, less or equally expensive as contrast enhanced MRI or diffusion MRI. It is also unclear if special equipment is necessary for this new MRI approach or if that equipment is currently common. Another cost not mentioned is the extra time needed to schedule the appointment and perform the imaging study.", "answer": 0}, {"article": "\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\nThey plan to continue modifying the test to improve the urine sensitivity to that of the cervical tissue samples.\nUsing the DNA from blood, they found the test had an 85.7 percent sensitivity and a 60.9 percent specificity.\nThe researchers tested the value of these genes as markers using 214 cervical cell samples collected from women undergoing Pap smears at Hospital Dr. Hernan Henriquez Aravena in Chile.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release suggests\u00a0that a urine test would be less costly than a Pap test, but it makes no effort to indicate what the cost is of either the proposed test or a Pap test.", "answer": 0}, {"article": "Jerry St. Peter, Vice President and Head of Sun Ophthalmics, added: \"A key strategic imperative for our ophthalmic business is to participate in the rapidly growing, underserved, and dynamic Dry Eye market, which is expected to reach $5 billion by 2020.\nLifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.\nSun Pharma announced successful Phase 3 confirmatory clinical trial results for Seciera\u2122 (cyclosporine A, 0.09% ophthalmic solution), for the treatment of dry eye disease.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this new product, nor is there any information on its needed frequency of use, which would be helpful to consumers considering it versus other products intended to curb dry eye symptoms. Another prescription cyclosporine ophthalmic product for dry eyes already on the market averages more than $400 for a one month supply (60 vials of Restasis 0.4ml).", "answer": 0}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nGonzalez said his team is working with the stroke prevention working group of the National Institutes of Health to develop a proposal for a Phase III randomized clinical trial across multiple institutions to further test the effectiveness of EDAS as compared with intensive medical management.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nThese patients received EDAS surgery, along with intensive medical management, which included diet and lifestyle changes, blood thinners and other medications to control blood pressure, cholesterol and blood sugar levels.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost although the surgical procedure used in the research is both already established practice and a complicated and extensive operation.\u00a0 Given that the surgery is being compared to simple medical management, the cost of the new approach will be substantially higher, and therefore deserves mention in this release.", "answer": 0}, {"article": "\u201cThe decision should be made after considering all the pros and cons.\u201d\n\nLead author Dr. Alexander Ford of the University of Leeds in the U.K. didn\u2019t respond to requests for comment.\nAnother drawback is that these studies weren\u2019t designed to prove how antidepressants or psychotherapy might directly improve IBS symptoms.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nA family of medicines known as tricyclic antidepressants were more effective at relieving global symptoms of IBS, the analysis found.\nWhile some people improve with customized diets that avoid certain foods that trigger symptoms, this approach doesn\u2019t help everyone and some emerging research suggests that the condition may also be influenced by processes in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed. Antidepressants and psychotherapy can be expensive, and are not always covered even for those patients with health insurance.", "answer": 0}, {"article": "Epilepsy is a neurological disorder in which the brain's normal electrical activity is temporarily disrupted, leading to a seizure.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\nStill, Mehta agreed that the technology could prove helpful to some people with epilepsy.\nOver those four months, the implants worked fairly well for eight patients -- correctly giving the high-risk warning anywhere from 56 percent to 100 percent of the time.\nBut experts said the results are promising, and should prompt further studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It seems that some cost estimate could have been projected by the device manufacturer which also funded the study.\nBut given the stage of the technology development we\u2019ll give the story the benefit of the doubt and grade this N/A.\nIt would have been appropriate to note that the device requires a neurosurgical procedure along with implantation, both relatively expensive propositions", "answer": 2}, {"article": "\u201cI was exhausted all the time, from the time I woke to the time I went to bed,\u201d says Turner.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nWhat's more, a recent study in the New England Journal of Medicine found that the bulky CPAP machines \u2014 standard treatment for many patients with sleep apnea \u2014 doesn't help prevent heart attacks or stroke, although it does help patients sleep better and improve mood.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\nThe main side effect from the device is that people can wake up with a sore tongue.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We learn: \u201cThe price tag for the Inspire device is $20,000, with surgery costing extra. Insurance companies are reviewing requests on a case-by-case basis.\u201d", "answer": 1}, {"article": "For more information, visit http://www.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nInvestigators conducted a randomized controlled trial in the pediatric Emergency Department at The Mount Sinai Hospital comparing lung ultrasound to chest X-ray in 191 children from birth to 21 years of age.\nThe research team was led by James Tsung, MD, MPH, Associate Professor in the Department of Emergency Medicine and Department of Pediatrics at the Icahn School of Medicine at Mount Sinai, and former clinical fellow Brittany Pardue Jones, MD, who's currently Assistant Professor in the Department of Pediatrics at Vanderbilt University School of Medicine.\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release earns praise for clearly mentioning the cost savings derived from the use of chest ultrasounds versus chest X-rays in treating patients in the study \u2014 $9,700 from 191 patients. The release could have been even even more helpful by adding information showing chest ultrasounds cost about two-and-a-half times less than chest X-rays ($140 versus $370 respectively). The release also might have mentioned that there\u2019s a large initial outlay for ultrasound machines that may make them too expensive in the developing world. Another upfront cost not mentioned is the expense of training emergency medicine physicians (and presumably also internal medicine, pediatric and family medicine physicians) to do this procedure.", "answer": 1}, {"article": "The apolipoprotein gene is inherited from each parent and when a patient inherits the ApoE4 variant from one parent they have a three times greater risk of developing Alzheimer's disease, whereas a patient who inherits ApoE4 from both parents is eight-to-12 times more likely to develop the disease.\nAs biochip tests allow clinicians and researchers to quickly run multiple tests on one sample of blood, this new test is also faster and more affordable than the standard DNA test, producing results in only three hours.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\n\"This type of testing is important in our quest to understand and diagnose Alzheimer's and empower patients to understand risks, consider medication, and even make early lifestyle changes.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release states that the biochip array is \u201cmore affordable than the andard DNA test\u201d but it doesn\u2019t provide a cost estimate for either.", "answer": 0}, {"article": "\"They take them because they have a disease that impacts their daily life,\" Economy says.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\nThe FDA advisory pointed to a single study showing a six-fold increased risk of a condition called persistent pulmonary hypertension in newborns whose mothers were taking antidepressants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. These costs for these medications vary widely depending on the SSRI, the manufacturer (i.e. brand-name vs. generic), and dosage \u2013 between $20 and $1,000 a month, according to Consumer Reports.", "answer": 0}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\nThey were also able to detect 100 percent of people with memory impairments who would progress to Alzheimer\u2019s disease within five years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story mentions neither estimates of the direct costs of such a test nor the indirect financial implications of testing before symptoms appear.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is mentioned, but\u00a0somewhat indirectly. Stating that \u201cinsurers generally reimburse about $5,000 for the procedure,\u201d is vague when ti comes to real costs.\u00a0Learning that \u201cMedicare covers it, though some private insurers do not,\u201d also is not that useful for men who might have to pay out of pocket for the procedure. Still, the cost information is more than what we typically see.", "answer": 1}, {"article": "Bone-marrow transplants, which infuse healthy blood cells taken from a donor, are used when chemotherapy and radiation fail to stop cancerous blood cells from taking over and ultimately destroying a person\u2019s immune system.\nBut she has been free of cancer for five years.\nThis expanded cord-blood technique has been a \u201chuge home run\u201d for patients, said Colleen Delaney of the Fred Hutchinson Cancer Research Center in Seattle, who helped create it.\nHis wife, Caryn, recalls how little they knew about his disease \u2014 acute myeloid leukemia \u2014 as doctors discussed treatment with them.\nQuinn, who has a science background, knew that finding a donor would be difficult.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the piece or whether the treatments are covered by insurance.", "answer": 0}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nFirst, patients are given drugs to stimulate production of blood stem cells.\nThe study was very small, and the procedure is not ready for widespread use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimate was given of the cost of this \u201ccocktail treatment.\u201d", "answer": 0}, {"article": "In other words, they are the precursors to muscle, fat, bone, and tendon tissue.\nRecently, researchers from the Stanford University School of Medicine have made it their mission to improve these outcomes.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nThey hypothesized that injecting stem cells into the brains of chronic stroke patients would increase their survival rates.\nAfter patients were sent home, researchers continued to monitor their health through blood tests, clinical evaluations, and brain imaging.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Because this story involved an experimental therapy in an early phase trial, formulating a probable cost of the treatment is premature. The story would have been strengthened, perhaps, by some indication of what stroke care and disability costs in lost productivity and health care expenses in the U.S.", "answer": 2}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nThe new study was presented at the annual meeting of the American Pain Society.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the regimen used in narcolepsy are discussed.", "answer": 1}, {"article": "The FDA is not required to follow the advice of its expert panels, but the agency typically does.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\nOf those patients, 136 had bleeding in the brain.\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Various estimates we found quickly online showed a cost of $7 \u2013 9 per pill \u2013 not a trivial issue!", "answer": 0}, {"article": "Politicians started giving scary speeches about rationing health care.\nThere\u2019s an intuitive argument for why 3-D mammography might be more accurate.\nOnly a prospective, randomized trial with mortality as its \u201cendpoint\u201d can say for sure, and that\u2019s how long it takes to conduct one.\n\u201cThe standard type of mammography that\u2019s used all over the country today may very well be better than what was used in that trial.\nHowever, the most meaningful data \u2013 the numbers that would show whether 3-D mammography saves women\u2019s lives \u2013 won\u2019t be available for decades.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The piece does state that \u201cthe technology does come with costs, financial and medical\u201d but the financial costs only refer to those incurred by the facility purchasing the equipment.\u00a0 There is no mention of financial costs to the patient who may have a higher co-pay due to the higher cost of 3-D imaging or may have two co-pays because the combo 2-D and 3-D mammograms \u201cconfer the most dramatic jump in benefits.\u201d\u00a0 There is also no mention of whether or not this\u00a0procedure will be covered\u00a0by most health insurance,\u00a0including Medicare.\u00a0 If 3-D imaging is not covered by insurance, the patient will have to cover the\u00a0cost.", "answer": 0}, {"article": "All rights reserved.\nApproval as an initial treatment likely would boost that sharply.\nIf approved, Tykerb \u2013 known as Tyverb in Europe \u2013 will be used along with another drug that prevents hormones from making cancer cells multiply.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\nTykerb had sales of $189 million last year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost \u2013 and Tykerb is a VERY expensive drug \u2013 thousands of dollars each month. ", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nZhang said his group may consider moving into another trial using only electroacupuncture on patients suffering milder depression.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimate was provided of what electroacupuncture for depression \u2013 nine times over 3 weeks as in the study \u2013 would cost.\nAcupuncture is almost never covered by insurance. \u00a0Each session costs > $100 in the U.S. \u00a0So a 9 session course is likely >$1,000.\nIn contrast, generic SSRI drugs are $4/month and if the patient responds well \u2013 about $50 of medication + doctor visits (we could estimate $400) that is covered by insurance.\u00a0 So out of pocket costs might be < $100.", "answer": 0}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nDr. Eric P. Winer, chief of women\u2019s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nThere was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Clearly stated.", "answer": 1}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report the cost of the drugs. \nWhile price is not essential in a story like this, as a rule costs should be reported.\u00a0 ", "answer": 2}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nBut the new criteria, which were developed by the National Institute on Aging and the Alzheimer's Association, are almost guaranteed to prompt confusion, even in people who are thinking quite clearly.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nAnd it's also because there are no treatments that can prevent, slow or stop early signs of Alzheimer's.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story clearly points out that brain scans and biomarker tests are \u201care to be used only for research, and not for diagnosing Alzheimer\u2019s in the general public.\u201d Since there are no recommended changes that directly affect readers today, and since it is not known which diagnostic tests may eventually prove useful, it is reasonable to put off discussions of cost.", "answer": 2}, {"article": "The researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\nFonarow said the study results can help cardiologists arrive at treatment decisions.\nIn preventing major cardiac events, the researchers found that zotarolimus-coated stents, the new entry in the field, were less effective than the sirolimus-eluting stents, but better than stents coated with paclitaxel.\nThe trial was partially funded by Medtronic, maker of the zotarolimus-eluting stent.\nFor the study, a team led by Dr. Duk-Woo Park from the University of Ulsan College of Medicine and Asan Medical Center in Seoul randomly assigned 2,645 patients undergoing angioplasty, a procedure to restore blood flow through the artery, to one of the three stents.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed.", "answer": 0}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nOne thing that is clear, the researcher stressed, is that Doppler ultrasound is not necessary for women with average, healthy pregnancies.\nResearch, according to Alfirevic, has moved on to other questions, including how to best manage abnormal findings from a Doppler scan.\nHowever, with Doppler an established technique for monitoring high-risk pregnancies, Alfirevic said it is very unlikely that any future studies will test Doppler against no Doppler \u2014 as most studies in this review did.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not give any estimate of the cost of Doppler ultrasound examinations.", "answer": 0}, {"article": "...\nWhy would a woman at normal risk of breast cancer want to get routine mammograms?\nThe obvious answer is that these tests save lives.\n\"The vast majority will turn out not to have cancer, but all of them will worry.\"\nIt is not wrong to want a routine mammogram, and it is not wrong not to want one.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not mention the cost or insurance coverage for mammograms \u2013 an unfortunate oversight given the nature of this story.\u00a0\u00a0", "answer": 0}, {"article": "Bracing is one of a number of noninvasive ways to treat knee OA and/or delay the need for joint replacement surgery.\nThe study was also presented at the recent annual meeting of the American Academy of Orthopaedic Surgeons in New Orleans.\nThe brace used in the study was provided by Ossur, which also provided financial support to the study through a research grant and sponsored the media briefing.\nNew research presented at a media briefing Tuesday in New York City suggests that Peterson is not the only one to find relief from knee bracing.\nAnd by and large, they did.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no mention of costs which can be signficant.", "answer": 0}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The original Associated Press story mentions the cost of of Pneumovax $30, and the original AP story also had questions about cost effectiveness of vaccinating younger, otherwise healthy college-age smokers.\nBut both points were cut out in the version published by the NY Daily News.\u00a0 ", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nAnd it\u2019s important for patients to know what type they have.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nWASHINGTON\u2014An experimental drug is showing promise against an untreatable eye disease that blinds older adults \u2014 and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even if we can\u2019t know the exact cost of what this drug might be (if it\u2019s approved\u2013that\u2019s TBD), we can surmise that it will be very high based on the price tags of every other drug in this class, known as immunotherapies. The story should have noted this.", "answer": 0}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nThe program led to a significant and clinically important reduction of pain, she said.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\nBut this study suggests these methods also can help reduce spinal pain, she said.\n\"They should also avoid the use of scary, unreassuring labels or diagnoses,\" and not limit movement in therapy, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The only mention of cost is at the very end. \u201cThe program, however, is quite time-intensive and is not covered by insurance,\u201d Patel said.\u00a0\u201cAlthough it\u2019s promising, we really have to see the benefit long-term to justify the cost,\u201d she added.\nThis isn\u2019t really enough information for a patient to know if it\u2019s within their reach.", "answer": 0}, {"article": "\"I could ride a bike!\nThere were other things the 12-year-old boy said he would do if he had two hands.\nEach electronic limb takes about 30 to 50 hours to make and assemble.\nIn truth, she had been more concerned about getting him therapy for his autism-related delays -- the limb difference was secondary.\n\"The adoration of college students was an affirmation that money can't buy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention costs, but in a way that is confusing and incomplete. In one place it says assembling an arm costs $20 to $50, then later it says the materials for an arm cost $350. The sort of 3D printers used can cost many thousands of dollars, but that expense does not seem to be included in this story. There is no mention of the costs of fittings or other expert services, or how long the limbs might last and how often they need to be replaced. Considering that conventional prosthetic arms cost thousands of dollars, the costs listed in this article are hard to believe.", "answer": 0}, {"article": "\"One caveat is that other agents that have shown clear efficacy in this model of PD have subsequently failed to show benefit in clinical studies in PD (e.g.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\nPlans for a clinical trial of low-dose lithium for PD patients are in early stages.\nThis study, published online in Brain Research, involved Parkinsonian mice that were given Carbidopa/Levodopa (sold as Sinemet\u00ae), a drug used to boost levels of the neurotransmitter dopamine, which is lost in PD.\nCitation: The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "After a misleading headline, the release establishes quickly that the research is in mice and that clinical trials haven\u2019t been performed. And at this early stage of development, the cost of treatment is not an issue. So we rule this Not Applicable. Having said that, if lithium augmentation of carbidopa/levodopa did indeed work in humans, the low cost of lithium is a distinct advantage to patients.", "answer": 2}, {"article": "Check it out if you're interested in finding a trial for yourself or someone you care about.\nThat suggests that a five-year follow-up period is not long enough to determine how well biomarkers can predict which patients will develop Alzheimer's disease, researchers say.\nKnowing which patient with mild cognitive impairment patients may go on to develop Alzheimer's is vital information for researchers, who are looking for treatments for the fatal brain disease.\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nThis is the longest clinical follow-up ever of patients who begin with mild cognitive impairment, researchers reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 Yes, we know that it\u2019s too early to use this in clinical settings, but the story makes the case that this builds on research following patients for as long as 12 years.\u00a0 Any predictive test would hold appeal for many people \u2013 so cost ramifications are important to discuss even at this early stage. Both tests are available at the present time so that with a little bit of digging, the costs could have been provided.", "answer": 0}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\nThe clinical trial included 22 patients with metastatic colorectal cancer who had been treated previously with irinotecan and whose disease was progressing.\nAlthough the study's main purpose was to test the safety rather than the effectiveness of guadecitabine doses, \"we were very happy to see some patients who benefited from the combination of the therapies for many months to more than a year,\" says Nilofer Azad, M.D., professor of oncology at the Johns Hopkins University School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this \u201cNot Applicable\u201d given the very early nature of the study and the fact that guadecitabine is clearly still far from approval for treating colorectal cancer so it would be difficult to put a precise dollar figure on it. It\u2019s worth noting, however, that guadecitabine is also being considered for use in treating acute myeloid leukemia (AML) \u2014 and is much further along in development for that clinical application. In fact, there is already discussion about whether the potential benefits associated with using guadecitabine to treat AML outweigh the fact that other drugs are available in generic form (and are therefore less expensive). In short, while we don\u2019t expect a release to place a dollar amount on the use of guadecitabine, we always like to see the issue of cost addressed in some way.", "answer": 2}, {"article": "Fader no longer holds that role.\nThe researchers say this may lead to new national guidelines for treating this cancer subtype, known as uterine serous carcinoma.\nShe notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nAdding the monoclonal antibody drug trastuzumab--already used to treat certain breast cancers--to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, which is unusual given that trastuzumab is already on the market (under various trade names) for use in breast cancer treatment. And the cost associated with those treatments is significant. For example, the cost of a trastuzumab treatment called Herceptin can cost $4,500 per month.", "answer": 0}, {"article": "SCOTTSDALE, Arizona - A migraine is much more than just a bad headache.\nThe U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura.\nBased on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.\"\nWhile there is no cure, a new study published in Cephalalgia in March shows single-pulse transcranial magnetic stimulation is a new way to prevent migraine attacks.\n\"The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,\" says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned.\nAccording to the American Psychological Association:\nA typical course of TMS therapy for depression involves 20 to 30 sessions, generally given in three to five treatments per week for four to six weeks. The full course of therapy with the pricey machines can cost $6,000 to $12,000.\nThis is consistent with other sources estimating the cost-per-session as approximately $400-500. Some (but not all) insurance plans cover TMS. Many insurance companies will require written justification from a physician for using TMS.\nIt\u2019s unclear whether patients would need to buy or rent the machine, and at what cost. ", "answer": 0}, {"article": "Lead researcher Professor David Newby, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"This relatively simple heart scan ensures that patients get the right treatment.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nThis is the first time that CT guided management has been shown to improve patient outcomes with a major reduction in the future risk of heart attacks.\nThis suggests that including the scans in routine care would not lead to a surge in costly tests or additional heart surgery, the researchers say.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release mentions that a computed tomographic angiogram (CTA) is cheaper than traditional angiograms but neither a cost or a rough cost comparison of the procedures is given.\nThere are also other costs to consider since a positive CTA will often lead to further testing. The study (but not the release) explained that further testing was examined as part of the analysis but no difference was observed \u2014 that\u2019s one of the strengths of this study.", "answer": 0}, {"article": "Systolic blood pressure, the top number, fell an average of nearly three points and diastolic dropped almost two points in the dark chocolate group, compared with no change in blood pressure readings in the white chocolate group.\nVolunteers for the study ate just over six grams of dark chocolate daily for almost five months \u2014 one square from a German chocolate bar called Ritter Sport, equal to about 1\u00bd Hershey's Kisses.\nTests suggested that steady exposure to dark chocolate prompted chemical changes that helped dilate blood vessels and regulate blood pressure, the researchers said.\nThey also kept food diaries so researchers could see if other foods might have influenced the results.\nSvetsky cautioned that weight gain from eating large amounts of dark chocolate would counteract any benefits on blood pressure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs, but most people know the cost of chocolate products, even ballpark costs of more expensive imports. ", "answer": 2}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The author does not mention the costs of the drug, which are likely to be substantial compared to the much cheaper cisplatin.", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nThe MUSC Health Weight Management Center takes a scientific approach to weight loss, focusing on changes in activity levels, behavior, thinking, diet and support systems.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that there are more than 20 million Americans with type 2 diabetes, but inexplicably says it \u201ccan lead to about $85,000 in medical costs,\u201d without noting if that is an average, lifetime, annual or other measure of diabetic \u2014 presumably per-person \u2014 health care costs.\u00a0We appreciate the nod to costs but nowhere is there any mention of the cost of Weight Watchers programs. In addition, the release promotes MUSC\u2019s weight management program but does not say whether insurance covers it, or anything about the costs of standard weight management and glycemic control efforts.\nThe release implies that this program will result in less cost when compared to medical costs of diabetes but that remains unproven.", "answer": 0}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n\"There is at least a significant chance this test will could falsely reassure some women and alarm others,\" said Eric Winer, a breast cancer expert at Harvard Medical School and a spokesman for the American Society of Clinical Oncology.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of this test $1,625 and mentions that insurance companies currently don\u2019t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO\u2019s speculation that insurance companies will eventually cover the test because it\u2019s easy to perform and \"any doctor can order the test\" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. ", "answer": 1}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nIn all patients, only one reduction technique was performed per patient.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost. According to the American Society of Plastic Surgeons, the average cost of breast reduction (for aesthetic patients only) is $5,631.\nSome insurance carriers don\u2019t cover cosmetic breast reduction surgery. In that case, patients must pay for the procedure out-of-pocket. The direct cost of either of the two procedures described could be increased if the results are undesirable.", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nThe study, conducted in Bulgaria, involved 140 healthy premenopausal women who had at least three UTIs in the past year.\nDr. Susan Bleasdale, medical director of infection control at the University of Illinois at Chicago, said the study \"may be a game changer\" for antibiotic \"stewardship\" programs aimed at reducing inappropriate antibiotic use.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although tap water generally costs very little, the sponsors of this research have helped turn bottled water into a multi-billion dollar industry. We\u2019ll rate the criterion Not Applicable, but some comment on the costs of bottled water wouldn\u2019t have been inappropriate.", "answer": 2}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nThe study is published in Drug and Alcohol Dependence.\nIt is one of the substances known as isoflavones found in kudzu.\nHe studied the extract puerarin.\n\"They still drank, but they drank less.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reader is likely to come away confused on this point. The story states that currently available kudzu supplements cost about $6 for 3 weeks of treatment, but it didn\u2019t clearly explain that these are not the same as the standardized extract tested in the study, which is not yet on the market and will likely cost much more if and when it is approved for sale.", "answer": 0}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nBut they found that the number of children born to a mother did not affect the results.\nThe study appeared online May 13 in The Annals of Rheumatic Diseases.\n\u201cBreast-feeding for an entire year is difficult for many women,\u201d said Dr. Mitra Pikwer, the lead author and an intern at Malmo University Hospital in Malmo, Sweden.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not mentioned but also not terribly important.\u00a0 ", "answer": 2}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\n\"Currently, we're not convinced that manipulation of HDL matters, though certainly it's promising,\" said Weintraub, who added that results should be available relatively soon from other trials exploring the issue.\n\"We have 94 percent confidence that this drug doesn't have the harmful effect that torcetrapib had, but we didn't prove a reduction in events,\" said Brigham and Women's Cannon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Because this story clearly points out that the drug is only part way through the clinical trial process and still has a long way to go before it might be on the market, we can excuse it for not giving cost estimates. Nevertheless,  It would have been informative for readers to have made some comment about the potential economic impact of a cholesterol drug, given that over 20 Million Americans are currently taking statin. On the day that the trial results were announced, Merck stock went up even though the market as a whole sagged, demonstrating the financial implications of this research.", "answer": 2}, {"article": "D.C.I.S.\nIn the meantime, Dr. Ford said, at least tamoxifen and raloxifene give women at risk the chance to do something.\nHalf the participants took one drug, and half the other for about five years.\nIf all 1,000 were treated, only 20 cases would occur.\nMore important, the difference between the numbers of side effects was not statistically significant, meaning that it could have occurred by chance and that the drugs could be similar or even the same.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were mentioned.", "answer": 0}, {"article": "Most American women begin to experience menopause around age 50, with some changes in their menstrual cycles earlier.\n\u201cThis requires a thorough exam and a thorough history, and individualized care, but women need to know: It\u2019s not a death sentence or a dependence.\nSuch custom compounds are not FDA-approved.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\nEven after the Women\u2019s Health Initiative news broke, some women couldn\u2019t face the changes without hormone treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the article.", "answer": 0}, {"article": "Enrollment ran from 1993 to 1998.\nWomen with the least-inflammatory diets had lower bone mineral density overall at the start of the study, but lost less bone than their high-inflammation peers, the researchers found.\n\"This suggests that a high-quality, less-inflammatory diet may be especially important in reducing hip fracture risk in younger women,\" the researchers wrote.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\nRebecca Jackson, the study's senior author and director of Ohio State's Center for Clinical and Translational Science, said the new findings support a growing body of evidence that factors that increase inflammation can increase osteoporosis risk.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs. This is not a typical intervention but more of a dietary lifestyle choice, but because the study in question talked about diets that were both high and low in inflammatory foods, it would be worth even a reference to what the costs associated with a more beneficial diet might be.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nTheir approach detects micrometastases, breakaway tumor cells with the potential to develop into dangerous secondary breast cancer tumors elsewhere in the body.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nThe approach may offer an improved way to detect early recurrence of breast cancer in women and men.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release would have benefited from information about the potential costs of enhanced MRI, and\u00a0about the overall current costs of current methods of breast cancer screening, diagnosis and therapy. The release certainly gives the impression that this technology could soon be deployed in humans, so some discussion of cost would be warranted.", "answer": 0}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nSo, the researchers theorized that the poor performance of the supplements may simply reflect the overwhelming power of the medications.\nIn fact, neither low doses of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are found in fish oil, nor of alpha-linolenic acid (ALA), derived from nuts and several vegetable oils, provided any benefit to the vast majority of heart patients, the study showed.\nAll had experienced a heart attack at some point in the decade leading up to the study, and all were taking blood pressure medications, anti-clotting drugs and statins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The margarines used in the study are not commercially available, so we can understand why cost of these formulations wasn\u2019t given (even if the story didn\u2019t disclose that the these were special non-commercially-available products). \nIt would have been interesting to learn how the costs of omega-3 fatty acid fortified margarine compares to a comparable, unfortified product.", "answer": 2}, {"article": "\u201cIt\u2019s a survival thing,\u201d she said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\nThe rising use of magnetic resonance imaging, MRI, is likely contributing to the increase in double mastectomies, said Dr. Joseph Leach, a medical oncologist with Park Nicollet Health Services.\n\u201cIf it\u2019s happening because of fear or the common reason I hear \u2013 \u2018I just want to be done with it\u2019 \u2013 that\u2019s a different situation.\u201d\n\nTuttle\u2019s study found 60 percent of women with breast cancer chose lumpectomies, which remove only the tumors, not the whole breasts.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While cost is very unlikely to drive a decision about breast cancer treatment, it\u2019s increasingly important for the media to educate readers about the true underlying costs of medical treatments. In this case, the reporter cites \"higher costs\" as one disadvantage of double mastectomy. This obligates the reporter to specify those costs. \nTo know how the cost of either a single or double mastectomy compares to the costs of lumpectomy plus radiation would have added additional value. ", "answer": 0}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not\u00a0include information about the cost of this medication.\u00a0According to recent Consumer Reports data, Lexapro at the dosages studied here would cost about $110 a month. This significant cost is something to bear in mind considering the modest benefit the drug confers compared to a sugar pill.", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the drug manufacturer speculates that sales will top $1 billion, the story gives no indication of what the cost is for the individual.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\nThe stimulation will hopefully jump-start the brain\u2019s recovery process and help them gain more control while undergoing standard therapy.\nAnd experts aren\u2019t even entirely sure why it works for Parkinson\u2019s in the first place.\nIf ultimately successful, DBS could become a treatment used in tandem with physical rehabilitation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While this story admittedly is announcing a new procedure never tried in human stroke patients, it conveniently glosses over the sheer complexity of what is being proposed\u2013intricate brain surgery\u00a0for stroke patients\u2013a procedure that inevitably will cost tens of thousands of dollars, and that if successful will actually only be an adjunct to aid in subsequent physical therapy following a stroke.\u00a0 Given that the story says that annually, nearly half of stroke patients will be disabled \u2014 400,000 \u2014 the cost of using this procedure on even a portion of those represents a staggering public health cost.", "answer": 0}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nTUESDAY, March 23, 2010 (HealthDay News) -- An ingredient in agave -- the plant used to make tequila -- may help fight bone-weakening osteoporosis and other diseases, Mexican researchers say.\n\"These results suggest that the supplementation of the standard diet with agave fructans prevented bone loss and improved bone formation, indicating the important role of agave fructans on the maintenance of healthy bone,\" Lopez said.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost not discussed but there is no product yet to cost estimate. ", "answer": 2}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThese trials employed a simple, economical design in which participants acted as their own controls (i.e., change in metabolic markers was measured before and after eating the bar).\nFormulation development was guided by over 15 small clinical trials to ensure that beneficial properties of the bar were retained.\nThese trials were conducted over a 4-year period using very similar bar formulations.\nDevelopment of the CHORI-bar has also been guided by Dr. Mark Shigenaga's insights into the importance of a healthy gut supported by optimal nutrition for disease prevention.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is nary a mention of cost, although participants in the clinical studies consumed two CHORI bars per day for a couple of months, suggesting anyone relying on this intervention will need to keep beaucoup bars in the pantry.", "answer": 0}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nEvery article is free online from the day of publication.\nTo Learn More: The full study is available on the For The Media website.\nThe article contains conflict of interest disclosures.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not include any cost information.", "answer": 0}, {"article": "The FASEB Journal, April 2017, vol.\nThese preliminary results are promising.\nMore research is needed to determine if compounds in red raspberries play a role in human cardiometabolic pathways.\nThese data corroborate a short-term study in humans reported by Xiao and colleagues at the same meeting supporting further work in humans to provide additional insight into these findings.\nBecause this study was limited to three meals, further research is needed to determine the factors that influenced outcomes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t refer to costs. ", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nThe analysis was more rigorous than most research based on pooling previous studies' results, because the authors obtained original data from each study.\nThe results \"provide the most robust evidence to date that acupuncture is a reasonable referral option,\" wrote the authors, who include researchers with Memorial Sloan-Kettering Cancer Center in New York and several universities in England and Germany.\nThe researchers concluded that the needle remedy worked better than usual pain treatment and slightly better than fake acupuncture.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that sessions cost $60 to $100 and are covered by some private insurance, but not Medicare.", "answer": 1}, {"article": "They\u2019re not producing the antimicrobials they need,\u201d he explained.\n\u201cIt\u2019s boosting the body\u2019s overall immune defenses,\u201d said Dr. Richard Gallo, dermatology chairman at the University of California, San Diego, who is leading the work.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\nNow scientists are mixing the good bugs into lotions in hopes of spreading protection.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is\u00a0preliminary research, but if it\u2019s not too early to speculate about benefits, it\u2019s not too early to discuss costs. Presumably this would be a special, prescription-only lotion, with a higher-than-average price tag compared with normal skin lotion.", "answer": 0}, {"article": "Experts are divided on the root cause of Alzheimer\u2019s and hence the best way to tackle it.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nThe drug\u2019s developers have since dropped the top dose from large ongoing Phase III trials.\nThe treatment was generally well tolerated, although two patients on the highest dose had transient brain swelling.\nThe new study, which only involved 28 patients, is modest fillip.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, nor was there even any mention that the drug needed to be administered via an injection \u2013 which will impact cost of delivery. \u00a0", "answer": 0}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nA formerly controversial high-fat diet has proved highly effective in reducing seizures in children whose epilepsy does not respond to medication, British researchers are reporting.\nBreaking the diet with so much as a few cookies can cause seizures to flare up.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story was not explicit about the costs of the diet. The ketogenic diet may involve inpatient initiation of treatment, lots of lab work and a good deal of involvement from the neurologist and dietician.\u00a0 The price of all of this may be offset by reduced drug costs.\u00a0 The listing of the components of the diet gives the impression of a low cost of care which may not be valid.", "answer": 0}, {"article": "Pregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\nThe Baylor scientists were able to correct for those variables.\nThe research in question involved mice, not women.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nSo maybe women who won\u2019t exercise for their own sake will do it for the baby.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The intervention here is the act of running\u2014in the case of these furry participants, running in an exercise\u00a0wheel. If the assumption is that the human equivalent is also running (and not weight lifting as the story\u2019s image indicates), the primary cost to people would be one of time.", "answer": 2}, {"article": "The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index.\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\nBethesda, MD (June 5, 2017) -- There may soon be a new tool in the fight against childhood obesity.\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes only that prebiotic supplements are \u201cinexpensive.\u201d A search of Amazon reveals a number of products with the same ingredients, in a wide range of costs. ", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the scans are expensive \u2013 $1000 to $3500 and are not necessarily covered by insurance. The story could have provided costs of the traditional neurologic exam for comparison.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of the glasses and lenses and that the lens costs could be recurring.\u00a0 It did not explain if insurance covers this approach.", "answer": 1}, {"article": "Scientists have found an unexpected use for virtual reality headsets: to help pinpoint people who may later develop Alzheimer\u2019s disease.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nBy identifying potential patients far earlier than is possible at present, researchers hope it should then become easier in the long term to develop treatments aimed at halting or slowing their condition.\nThese studies used tablet computers to test navigational tasks.\nThis now appears to be the first part of the brain that succumbs to Alzheimer\u2019s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. And there are multiple costs to consider here: the cost of the virtual reality (VR) hardware itself, the cost of whatever software the study participants would be using, and the cost of training professionals to interpret the data generated by study participants using the virtual reality technology. (Note: we say \u201cstudy participants\u201d because there are no patients yet, but \u2014 ultimately \u2014 the cost to patients is what we\u2019d be interested in.)", "answer": 0}, {"article": "Even incurable causes of age-related vision loss such as glaucoma and age-related macular degeneration \u201care highly treatable, so we can reduce the amount of vision loss that people suffer from if they\u2019re detected early.\u201d\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\n\u201cThis study provides additional evidence that would suggest that people who can keep their vision healthy as they age might also be protecting their cognitive health,\u201d said Dr. Heather E. Whitson of Duke University School of Medicine and Durham VA Medical Center, who wasn\u2019t involved in the research.\nOver the course of the study, average visual decline was roughly equivalent to losing the ability to read one line of an eye chart.\nThe results suggest that vision fixes, like a new eyeglass prescription or surgery to remove cataracts, can go a long way toward helping older people stay mentally sharp, said lead author D. Diane Zheng of the University of Miami Miller School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Maintaining visual capabilities does not come cheaply in the United States, given the need for diagnostic visits, eyewear that can run into the hundreds of dollars, and expensive medical procedures to manage a litany of age-related problems, such as cataracts and macular degeneration.\u00a0 Although the story\u00a0mentions these options, their related costs are missing in action.", "answer": 0}, {"article": "The surgically reconstructed knees and the conservatively treated joints experienced similar (and high) levels of early onset knee arthritis, a common occurrence after an A.C.L.\nThe authors of the study are less sure.\nTwenty-three subjects of that group did eventually have the operation.\nThe ultimate lesson of The New England Journal study is almost certainly that more science on the subject is needed.\nIt may be years, unfortunately, before we know if such expectations are justified or if unreconstructed injured knees can be fine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The author briefly mentions that the operation \"can be expensive.\" A little more detail about the costs and economic forces would\u2019ve been great. We consistently grade such vague references as unsatisfactory. ", "answer": 0}, {"article": "About the American Urological Association: The 111th Annual Meeting of the American Urological Association takes place May 6 \u2013 10 at the San Diego Convention Center in San Diego, CA.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nIt is often administered as a gel, patch, injection or implant (pellet).\nThey returned at weeks 26, 39 and 52 for safety assessments, which included an evaluation of adverse events, clinical laboratory tests and physical examinations.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of this would-be product were not addressed even though it is under review by the FDA and potentially months away from approval.", "answer": 0}, {"article": "\"You don't get back the time you lost at work or the time you lost with your children.\"\nBut about 80% will get relief, he says \u2014 defined as a headache reduction of at least 50% \u2014 after trying three or four drugs, alternative remedies and lifestyle changes.\nBut nearly 40% have headaches that are so frequent (at least once a week), severe or hard-to-treat that they qualify, Silberstein says.\nFinding the right medication for the right patient can take a lot of trial and error and careful dosing, Silberstein says.\nThe guidelines list seven prescription medicines and one herbal remedy backed by strong evidence, and include many other treatments that might work for some patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. As the guidelines state, \u201coverall cost is a consideration when prescribing medications; cost may influence compliance, especially long-term.\u201d", "answer": 0}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nTamoxifen is the only hormonal option for women before menopause, Litton says.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\nGray noted that tamoxifen has risks.\nJordan says the new findings will quickly change care for some patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did a good job discussing costs.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nThe researchers caution that the reliable detection of small to moderate risks and benefits of drug therapies requires cogent data from large-scale randomized trials designed a priori to test the hypothesis.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release explicitly urges the widespread use of Chantix, it does not discuss cost \u2014 and cost can be a considerable obstacle. Online estimates of cost related to Chantix vary widely, but all of them indicate that a prescription would cost well over $100 per month.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nWickii Vigneswaran, MD, presented the study during the 2016 annual meeting of the American Society of Clinical Oncology.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the news release. Pleurectomy and decortication is a major two-part surgery requiring use of an operating room, post-operative recovery services and hospitalization as well as surgeon fees. Although the average age of the patients was 70 years, they ranged from 50 to 80 years. While Medicare coverage is available for those over age 65, it may not be for those under.\u00a0 A ballpark range of the surgery cost would have been helpful for both reporters and consumers, which is why we give the news release a \u201cNot Satisfactory\u201d rating here. ", "answer": 0}, {"article": "Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nCoauthors Lana Warren, EdD, OT/L and Patricia Rao, PhD, Kennedy Krieger Institute, Baltimore, MD, and David Paton, DAc, LAc, Starting Point Acupuncture and Health Services, Catonsville, MD, identified the most positive outcome of the study as the high compliance rate, with all parents of the children ages 3-10 completing the intervention.\nIn the article entitled \"A Pilot Observational Study of an Acupressure/Acupuncture Intervention in Children with Autism Spectrum Disorder,\" most parents reported that the intervention had a positive impact on their relationship with their child.\nThe researchers measured the effects of the intervention on factors such as the children's behavior, ability to pay attention, sleep, and aspects of parenting stress.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned at all. The costs of acupuncture treatment can vary widely, but most people can expect to pay at least $60 per session (and often considerably more). Given that this study involved 16 sessions, and that not all health plans would cover acupuncture to treat ASD, the expense could be considerable.", "answer": 0}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nBut Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\nIt\u2019s a kind of introduction that familiarizes the T-cells with the body\u2019s normal cells.\nThese new nanoparticles stopped the course of a MS-like disease in mice, the researchers found.\nIf the treatment was done as soon as the mice had their first MS-like attack, the attacks stopped.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes a researcher saying that one stage of the research\u2026\u201dwas hideously expensive.\u201d \u2026 \u201cIt cost probably about a million dollars to treat 10 patients using live cells,\u201d he said.", "answer": 1}, {"article": "The F.D.A.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nNovartis is sponsoring another study to see if the drug is effective for those with preserved ejection fraction, which accounts for half of heart failure cases.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does an excellent job here. Not only does it provide the predicted daily and annual cost of the drug ($12.50 and $4,500, respectively), but explains why some health plans may balk at the price (given that competing drugs are significantly less expensive).", "answer": 1}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\nMore in-depth studies are needed before researchers can say that the magnesium was what actually reduced the stroke risk, she added.\nOther experts said the results were consistent with dietary recommendations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of such a diet is not in question.", "answer": 2}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to discuss the new drug\u2019s cost or even cite the price of its chief competitor. \nIt may be difficult to project a drug\u2019s cost before it\u2019s on the market. But these drugs are expensive [Plavix, the incumbent anti-clotting blockbuster, is $4 per day] and readers should realize that.\nBecause the story focuses on the potential of Brilinta to knock off Plavix, some discussion of price should have been included. The economic stakes are high not only for the industry, but for the public and individual consumers.", "answer": 0}, {"article": "HPV is the most common sexually transmitted disease.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nThe anticipated cost of the vaccine, administered in three shots over six months, is $300 to $500, a possible impediment to widespread vaccination campaigns.\nMerck said the vaccine could be used in females age 9 to 26, but would work best when given to girls before they begin having sex.\nPending action by the FDA, the national Advisory Committee on Immunization Practices will decide in June whether to endorse routine vaccination with the vaccine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, which are likely to be substantial given the scope of a potential vaccination program. Furthermore, because women will likely still have to get pap smears, an HPV vaccination program is unlikely to save money. The cost of the three injections are estimated to be around $500. The cost of a nationwide screening program would be in the billions of dollars.", "answer": 0}, {"article": "\u201cThe decreased risk of breast cancer in this group is something we totally didn\u2019t expect when we started the W.H.I.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nThe trial has, however, been held up for years as the gold standard for medical research, and its findings linking combination hormones to breast cancer and heart problems led to significant changes in the way doctors around the world treated menopause.\nAlthough all the women in the estrogen study stopped using the treatment in 2004, the investigators have continued to monitor their health, as is typical in large clinical trials.\nThe new findings, reported Tuesday in The Journal of the American Medical Association, come from 10,739 women in the Women\u2019s Health Initiative study who had previously had a hysterectomy, the surgical removal of the uterus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not touch on costs.", "answer": 0}, {"article": "Learn more about omega-3 fatty acids, including DHA, and infant health from the March of Dimes.\nBut, she added that the supplements did appear to be safe for pregnant women to take.\nThe treatment group received 400 milligrams of DHA each day, beginning when they were between 18 and 22 weeks pregnant.\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost of DHA supplementation. We easily found many websites selling plant-source (from algae) DHA. One site had a bottle of 60 (only 200 mg tabs, so the mother would need to take 2 to reach the 400 mg in the study) for $19.67.", "answer": 0}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nWhile around 60 million people play golf at least twice every year, the participant profile is quite narrow: players tend to be middle aged to older, male, of white European heritage, relatively well off, and living in North America, Europe, and Australasia.\nAmid a growing body of evidence on the health impacts of the sport, the consensus aims to help current and would-be players maximise the health pros and minimise the health cons of golf, and to guide policy-makers and industry leaders on how best to make golf more inclusive and accessible and so encourage more people from all walks of life to take up the sport.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release states that golfers tend to be \u201crelatively well off\u201d and:\n\u201c\u2026 the sport is often perceived as expensive \u2026 and not a game for the young or those on the lower rungs of the social ladder\u201d\nThe cost to play 18 holes at the course closest to where this review is being written is $27. The fee at St. Andrews Royal and Ancient Golf Club in Scotland \u2014 where one of the authors is director of Golf Development \u2014 is roughly 10 times that amount.", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nTherefore, the method that is applied worldwide is to artificially feed these children during the first days of their stay in intensive care.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We rated this Not Applicable since giving parenteral (IV) nutrition seems to be done routinely and this study reviewed withholding it (which should save money). The biggest cost saver might be fewer days in the ICU. Some discussion of the cost-benefit analysis of changing the protocol might have been helpful to readers.", "answer": 2}, {"article": "#Nosmokingduringpregnancy.\u201d\n\nAbout the American Journal of Respiratory and Critical Care Medicine\n\nThe AJRCCM is a peer-reviewed journal published by the American Thoracic Society.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nThis study was funded by the National Heart, Lung, and Blood Institute and the Office of Dietary Supplements.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost of vitamin C supplementation is not mentioned.\u00a0 Most people are aware that vitamin C is relatively inexpensive.\nAccording to Walmart, CVS, and Amazon, a 100-day supply of 500 mg vitamin C tablets costs roughly $5.", "answer": 2}, {"article": "Another difference is that Zostavax contains a live, weakened virus, making it unsuitable for people with poor immunity, whereas Shingrix contains a nonliving virus particle and may eventually be approved for those with compromised immunity, who are especially susceptible to a severe case of shingles.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\nBut for about 15 percent of people, shingles does not end there.\nHere\u2019s how it compares to its predecessor Zostavax, which over all reduces the risk of shingles by 51 percent and of PHN by 67 percent.\nAlthough most people get shingles only once, it can happen again, especially if you have a weakened immune system, which most everyone does with advancing age.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter noted that the \u201clist price is $280 for the two-part shot without insurance.\u201d\u00a0 Since Medicare Part D insurance covered it with a $40 co-pay for each part it is likely affordable for many people.", "answer": 1}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nRogers\u2019 sweat patches are designed for one-time use over a few hours.\nBy simply looking at a color change, \u201csuch a patch allows people to now have an opportunity to understand their health and how it changes depending on activities.\u201d\n\nIt\u2019s a growing field: Other research groups around the country, including some of Bao\u2019s colleagues, are pursuing wearable biosensors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of this patch or of a comparison approach involving sending absorbent pads to a lab aren\u2019t addressed.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The column includes a cost estimate for the products mentioned.\u00a0 This column is consistently good about including cost information.", "answer": 1}, {"article": ".\n\"High-frequency ultrasound provides almost microscopic resolution and enables us to get size, shape and extent of the lesion prior to biopsy.\"\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\nIn another study scheduled to be presented at the meeting, researchers found that high-frequency ultrasound with elastography can help distinguish between cancerous and benign skin lesions, which could improve the efficiency of skin cancer diagnosis.\nSiegel and his colleagues used ultra-high-frequency ultrasound to image cancerous and benign skin lesions on 40 people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the cost of elastography.\u00a0The use of a second additive technology will clearly add to the costs of diagnosis unless the sensitivity and specificity of the test is sufficiently high to reduce unnecessary biopsies. The potential cost implications of this added technology are not noted in the story.\u00a0 Although the true economic impact of the technology is not known at present, the potential cost implications of the method should have been noted.", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No treatment costs are discussed. According to a 2015 study in the journal Future\u00a0Oncology, the average cost per hospital stay was $12,268, while outpatient clinic visits tallied about $4,364 per visit (surgery and radiation). However, given multiple visits, the typical prostate cancer patient can expect a lifetime cost of about $110,000.\nBut adding in hormone blockers, also called androgen deprivation therapy, according to a 2007 study in The Journal of Urology, can double the cost of a man\u2019s care. Since newer drugs are being used, those costs also should have been included.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nEvolve BioSystems' Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a baby's gut and reduce potentially harmful bacteria by 80 percent.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nHaving led to the development and commercial launch of products to resolve newborn gut dysbiosis, including Evivo\u00ae for infants, Evolve's discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The only dollar sign in this release is a notation that Evolve BioSystems obtained $40 million in recent funding.\nThe release states the Evolve stool-testing device is a prototype, so we\u2019ll give that a pass \u2014 it implies it can\u2019t be purchased.\u00a0But not listing the price of the Evivo probiotic, which is described later, doesn\u2019t get a pass: The two are inextricably linked by the release, i.e. babies with low levels of Bifidobacterium\u00a0would be given the probiotic.\nThe Evivo probiotic product ranges from $80 for a one-month supply to $335 for a six-month supply, though it is unclear how long a baby is supposed to take it.", "answer": 0}, {"article": "Publication: 'The Stockholm III Trial on optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer - a randomised controlled trial' Johan Erlandsson, Torbj\u00f6rn Holm, David Pettersson, \u00c5ke Berglund, Bj\u00f6rn Cedermark, Calin Radu, Hemming Johansson, Mikael Machado, Fredrik Hjern, Olof Hallb\u00f6\u00f6k, Ingvar Syk, Bengt Glimelius, Anna Martling\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\nA new study from Karolinska Institutet in Sweden shows that short-course preoperative radiotherapy combined with delayed surgery reduces the adverse side-effects of rectal cancer surgery without compromising its efficacy.\nHowever, radiotherapy can cause adverse reactions and the optimal radiotherapeutic method and the interval between it and the ensuing surgery have been mooted.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs. Perhaps just changing the timing of the same treatments is cost neutral, but maybe not. It would be interesting to know if\u00a0delaying surgery affects total treatment costs, particularly if it results in fewer complications. One 2009 study put the mean total colon cancer cost per U.S. Medicare patient at $29,196, noting that the cost for rectal cancer is substantially higher.", "answer": 0}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\nPrior studies of massage for back pain had tested only structural forms of massage, not relaxation massage.\nIn some cases, researchers report, the benefits of massage lasted for six months or longer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Massage, too, has a cost, and could have been ballparked at the very least.\u00a0 What do 10 sessions of massage therapy cost?\nThe study reported that the massage treatments \u201cwould have cost about $540 in the community.\u201d The study goes on to state, \u201cThere is no evidence that these treatments reducted costs of back pain-lreated health care services during the 1-year posttreatment period.\u201d This information could have been easily conveyed.", "answer": 0}, {"article": "Todd McAllister of Cytograft Tissue Engineering in California and colleagues implanted lab-grown blood vessels into 10 patients with advanced kidney disease in Argentina and Poland from 2004 to 2007.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nThe study was was paid for by Cytograft Tissue Engineering.\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included an estimate that tissue-engineered blood vessels could cost more than $15,000, perhaps making them too expensive for wide use.", "answer": 1}, {"article": "Co-authors include: Drs.\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\n\"Although sedation-related serious adverse events occur infrequently, recognition and early intervention is necessary to ensure patient safety,\" said Dr. Maala Bhatt, lead author, director of pediatric emergency research at CHEO, and assistant professor at the University of Ottawa.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost. The costs of a visit to the emergency room can be extensive with the cost of sedation a relatively small part of the overall cost. Even so, ballpark costs of sedation would have been helpful to include.", "answer": 0}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\nThe new study seems to make a powerful argument in favor of PSA testing.\nStudies looking back at cancer trends in a population are very unreliable when it comes to showing what caused those trends.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no cost information in the story, and this is a big gap seen in other stories that covered the topic \u2013 in TIME.com and HealthDay. Mentioning the cost of a PSA test and whether insurance typically covers it would have been great, as well as the costs of some of the subsequent tests and treatments.", "answer": 0}, {"article": "\"With my technique, there is a much more limited scar and it limits the scarring in the fold of the breast, which is usually the most uncomfortable. By the third day, most women are up and around and doing most of their activities.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention the cost of breast reduction, which ranges from $6,000 to $10,000. \nThe story includes the fact that insurance sometimes pays. But readers would be curious to know what might qualify/disqualify women for coverage.\u00a0 ", "answer": 0}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not address the cost of obtaining CPR training, nor the cost of providing it. While some training events are free, courses available from the American Red Cross in the Portland, Maine area range from $70 to $110.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nIt has been suggested that as treatment for atrial fibrillation, the Watchman device may be preferable to standard blood thinning medications, such as warfarin, which raise the risk of bleeding.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not say how much the new device costs, nor does it say how\u00a0it compares with the cost of warfarin or non-warfarin oral anticoagulants.\nThis is of concern, since the news release focuses on the cost-effectiveness of the device.", "answer": 0}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\nBoosting this synchronous brain activity appeared to act as a cue for the brain\u2019s immune cells, prompting them to absorb the sticky amyloid proteins that are the most visible hallmarks of the disease in the brain\u2019s of people with Alzheimer\u2019s.\nCloser inspection showed that the amyloid had been taken up by microglia, the brain\u2019s immune cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story\u00a0does include a hint from the senior author that the treatment would be \u201caccessible,\u201d and presumably the cost of flickering lights would be an issue for most people.", "answer": 2}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned \u2014\u00a0not acceptable\u00a0when the drug is already on\u00a0the market and cost information is\u00a0easily obtained. According to one estimate\u00a0our reviewer found within minutes,\u00a0treatment with Avodart costs about\u00a0$4 per day. Previous analyses of finasteride, which has a similar mechanism of action, estimated that the cost per quality-adjusted life year (QALY) gained from treatment far exceeds $100,000/QALY. An acceptable cost effectiveness for a treatment is considered to be less than $50,000/QALY.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nBut Dr. Tice warned that the drugs should not be used long term.\nThere were only two studies for Effexor, just one of which suggested it might help.\nAll the nonhormonal drugs have side effects.\nShe took a cautious view because she and her colleagues found that there was relatively little reliable data on using the drugs for hot flashes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of hormonal or non-hormonal treatments, which would be important to note if they are taken daily (or several times a day for some medications) for several months or years. ", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\nBut one-quarter of those given CT scans were found to have anomalies, nearly all of which were benign.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nMixed bag and, in the end, not specific enough to warrant a satisfactory score. \nThe story does say that a nationwide lung cancer screening program would be \u201cenormously costly,\u201d and it does mention that screening leads to additional tests and treatments. But what does \u201cenormously costly\u201d\u00a0mean? And how much could those additional tests and treatments cost? \nThe story doesn\u2019t tell readers that this type of CT scan costs about $300 (or that the trial participants each received about $900 worth of scans) and that this type of screening is generally not covered by insurance.", "answer": 0}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nA previous study by the same authors showed that low doses of aspirin (75-300 milligrams) reduced the number of cases of colorectal cancer by a quarter and deaths caused by the disease by more than a third.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\nThe investigation also showed that the benefits of taking aspirin increased over time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss the cost of daily aspirin intake. Because the cost to individuals is low and well-known, we won\u2019t insist on this point. Nevertheless, were a recommendation made for everyone to begin taking aspirin daily starting at age 45 the national price tag would be substantial. Readers would also benefit from an acknowledgement that such a recommendation would lead to higher spending on treatment of bleeding ulcers and other adverse events that would offset some of the potential cancer-related savings.", "answer": 2}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nAvailability of a blood test for concussion will help health care professionals determine the need for a CT scan in patients suspected of having mTBI and help prevent unnecessary neuroimaging and associated radiation exposure to patients.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe FDA evaluated data from a multi-center, prospective clinical study of 1,947 individual blood samples from adults with suspected mTBI/concussion and reviewed the product\u2019s performance by comparing mTBI/concussion blood tests results with CT scan results.\n\u201cA blood-testing option for the evaluation of mTBI/concussion not only provides health care professionals with a new tool, but also sets the stage for a more modernized standard of care for testing of suspected cases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes the cost of CT scans as if the blood test costs nothing. In reality, the blood test could cost more than the CT scan (plenty of blood tests already do) and the comparison drawn is meaningless.\u00a0 The release should have noted whether the blood test could be done in a standard lab or would require specialized techniques, which would affect cost, and how the 3-4 hour minimum timeframe to process the blood work would realistically impact the workflow in emergency department settings. \nWe applaud the release for at least acknowledging cost concerns.\n\u201c\u2026availability of a blood test for mTBI/concussion will likely reduce the CT scans performed on patients with concussion each year, potentially saving our health care system the cost of often unnecessary neuroimaging tests.\u201d\nBut there\u2019s no cost data given to back up that assertion.", "answer": 0}, {"article": "Separate strands of material become stronger when they link up.\nThe cream\u2019s effects are detailed in a scientific report in the journal Nature Materials, but as part of the school\u2019s close association with the companies, it\u2019s being patented and produced at almost the same time.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offers no information on the cost of the would-be product, nor of how expensive the components of this new material is, even though the story emphasizes that the technology is being licensed for commercial applications. Even if it\u2019s too soon to know the precise cost, a ballpark figure is useful.", "answer": 0}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story excels in this criteria where so many others fail. The story says, \"The program costs about $1,600 for 12 weeks,\" and then it goes on to make an\u00a0important comparison. \"Compare that to the $19,000 to $29,000 cost of bariatric surgery, which is often reimbursed by insurers.\" This helps readers understand that dieting is a far cheaper approach to weight loss, and that the burden of expensive weight-loss surgeries is actually passed onto all of us in the form of higher insurance premiums. We wish the story had driven home the point more emphatically \u2013 as it alluded to in the headline and in one line in the story \u2013 that people in the trial got the intervention for free.\u00a0 That\u2019s a big leap from reality. ", "answer": 1}, {"article": "It was a turning point, and for the next year I continued to get better.\u201d\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nA handful of medications meant to help left him feeling like a zombie, and he gave them up.\n\u201cThe MDMA alone or the therapy alone don\u2019t appear to be as effective,\u201d Dr. Mithoefer said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of MDMA is not mentioned, and likely difficult to forecast.\nHowever, the associated therapy is fairly intensive, and it remains to be seen if it would be covered by insurance. Still, a discussion of these potentially significant costs would have been relevant and helpful, even if the story admits they\u2019re largely unknown.", "answer": 0}, {"article": "ASDs mainly affect a person\u2019s social interaction and communication, with symptoms that can include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty adapting to new environments.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\nWe hope the tests will also reveal new causative factors.\nFor example, we don\u2019t know whether this technique can distinguish autism from ADHD, anxiety or other similar conditions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs for the blood and urine tests mentioned in the story are not included. A cost estimate might be speculative at this point, but it seems reasonable to expect some discussion of what specialized tests like this might cost.", "answer": 0}, {"article": "For more about blood pressure drugs, visit the American Heart Association.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nAlthough ACE inhibitors were developed 10 years earlier, both types of drugs showed similar effects in the analysis, challenging previous findings that suggest ACE inhibitors have greater benefits.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\nBoth ARBs and ACE inhibitors interfere with the function of a hormone called angiotensin II, which regulates blood pressure, but they do this in different ways, the study authors said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give the story a grudging satisfactory in this category since it mentions, as a closing statement, that many ARBs are now generic, which means their cost is lower than brand-name equivalents.\u00a0 But the story would be more helpful to readers if it provided an idea of the comparative costs for the two types of drugs, as well as an average annual cost, since patients remain on them for long periods of time, if not for life. Though more ARBs are now available generically, the costs of generic ARBs generally remain higher than for ACEIs. For many doctors and patients, the use of ACEIs may still be preferred simply because they\u2019re cheaper \u2013 even given similar efficacy and a slightly greater need to stop them due to side effects.", "answer": 1}, {"article": "Other Northwestern authors are senior author Dr. Ronald Ackermann and co-authors Mercedes Carnethon and Dr. Namratha Kandula.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nThis is the first study to report how these expanded screening criteria would perform in practice among a nationally representative sample of U.S. adults.\nBut O'Brien said it is unclear whether insurers will be required to pay for diabetes screening if patients only meet the expanded criteria.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the screening test is not mentioned. But while the testing itself is low cost, the downstream and societal costs are ignored in the release. Costs could be very significant for expanding screening for a surrogate marker for diabetes that may or may not be a problem. The drugs, blood glucose testing, and checking and rechecking of blood sugars is a huge industrial enterprise that involves significant medical resources.\nThe release does address cost in terms of what it currently costs ($327 billion annually) to treat \u201cprediabetes\u201d (a condition that may not develop into diabetes) and people with type 2 diabetes. It would have been fair of the release to include the estimated cost of additional screening, tests and treatment being proposed.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the test is still under study, the costs of a diagnostic test is an important consideration even in reporting on a drug under study. \u00a0PET scans are extraordinarily expensive, so much so that the business implications are noted but the costs are not. \u00a0Noting the expected size of the market for this test without discussing projected or estimated cost of use even in vague terms seems inconsistent.\u00a0 ", "answer": 0}, {"article": "\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\nThat means the device only stimulates the vagus nerve when the stomach moves.\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThat ongoing maintenance can be a big barrier to use, says Luke Funk, a surgery professor in UW-Madison's Division of Minimally Invasive, Foregut and Bariatric Surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this device is still in early testing, the news release notes that it is intended to improve upon a similar device that is already available. The procedure to implant the existing device may cost more than $20,000. This release could have told readers what the current price range is for such a device. If the researchers have reason to expect their device to be more or less expensive than the existing device, that information should be included.", "answer": 0}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about costs, which was disappointing. The costs of intensive medical therapy can easily be identified. Using an online pharmacy we calculated the costs to be about $1,500 to $2,000 annually for medical therapy, using generic drugs. Using the Health Care\u00a0Blue Book, we found the average cost of coronary artery bypass sugery and hospitalization to be about $62,000. We think that this is important information for readers that should have been included.", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\nThat study found a benefit when 5-Hour Energy was compared to a placebo like flavored water, she said.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that energy drinks are expensive compared with other sources of caffeine, such as coffee or caffeine tablets. A 16-oz can of monster sells for $2.99.", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll assume that costs of sex are generally Not Applicable for readers (although erectile dysfunction drugs are certainly big business and can be costly). We won\u2019t penalize the story for not addressing costs here.", "answer": 2}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nFor now, much of the attention in the world of liver disease is on two drugs -- telaprevir and boceprevir -- that Schiff expects will become available within the next year and a half.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since BMS-790052 is still in early testing, we don\u2019t know what it will cost, so the criterion is not applicable.\u00a0However, given the huge costs of the existing treatment regimen of an interferon and ribavirin, a comment on the potential economic impact of a third drug would have been helpful.\u00a0 Current treatments cost several thousand dollars per month with treatments lasting for 6-12 months.\u00a0 The addition of a third and presumably expensive antiviral is an important aspect of the costs of treatment.\u00a0", "answer": 2}, {"article": "It will enable us to have more potent countermeasures to jet lag than continuous light, which is the current prescribed light therapy treatment,\" Zeitzer said.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThis time around, researchers tried to further optimize the process.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThe treatment could benefit not only travelers but also overnight shift workers and people with constantly changing schedules, he said, but that's a long way off.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. How much would a device that emits a flashing light that delivers a camera-like flash every ten or so seconds cost? It could be a little or a lot, depending on the purchaser. The competing Reuters story at least suggested that this device would require complicated new technology that one can presume might be costly.", "answer": 0}, {"article": "Heart disease is the leading cause of death in the Western world.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\nIn a report published in the journal Pediatrics, they call for screening of all children, expanding one set of current recommendations that target only those whose parents or grandparents have heart disease or high cholesterol.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nBut a third of those children didn\u2019t have relatives with heart disease or high cholesterol, and so wouldn\u2019t have been screened under the current guidelines, issued by the government\u2019s National Cholesterol Education Program.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story says universal screening would be expensive, but it does not provide any dollar amounts. Cost is clearly relevant to the story. The researchers blame the lack of health care insurance for the high proportion of parents and grandparents of these children who have never had a cholesterol test. The story does not address the issue of how families would pay for ongoing treatment if doctors prescribed it.", "answer": 0}, {"article": "The editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were surprised to see that a story that covered as much ground as this one did somehow missed costs. The competing story by NBC spelled out the costs.", "answer": 0}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nAfter nine days, the researchers found a 33 percent drop in triglycerides, a type of fat tied to heart disease; a 49 percent reduction in a protein called apoC-III that is tied to high triglyceride levels; and large reductions in small, dense LDL cholesterol, a risk factor for heart disease.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The brief text reflects only on removing highly sugared foods\u00a0in the diet of children.\u00a0 Replacement foods used in the study were commonly available at no obvious extra cost.", "answer": 2}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\nAt the beginning and end of each diet period, participants spent three days undergoing metabolic testing in a clinical research setting.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\nWednesday, Oct. 19, 2016, Cleveland: A team of Cleveland Clinic researchers, in collaboration with Nestl\u00e9 Research Center, conducted one of the largest controlled studies of its kind on whole grains and concluded that a diet rich in whole grains may significantly lower the risk of cardiovascular disease in overweight and obese adults under the age of 50.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There were no mentions of costs in this release, which\u00a0is unfortunate since a simple statement could have informed readers that both whole grain foods and refined grain foods are readily available and are usually similar in cost.\u00a0", "answer": 0}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThat said, these experimental drugs carry the potential for serious side effects, including causing the immune system to go haywire.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\n\"This is problematic in that use of these treatments may carry a very high risk for neurologic complications, thus necessitating heightened monitoring, and diminishing its applicability as a treatment for a larger patient population such as the Alzheimer's disease population,\" she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs wouldn\u2019t be discussed in such early research.", "answer": 2}]